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 32 
ABSTRACT  33 
 34 
Coevolution of humans and malaria parasites has generated an intricate balance between the immune 35 
system of the host and virulence factors of the parasite, equilibrating maximal parasite transmission with 36 
limited host damage. Focusing on the blood-stage of the disease, we discuss how the balance between 37 
antiparasite immunity versus immunomodulatory and evasion mechanisms of the parasite may result in 38 
parasite clearance or chronic infection without major symptoms, whereas imbalances characterized by 39 
excessive parasite growth, exaggerated immune reactions or a combination of both cause severe 40 
pathology and death, which is detrimental for both parasite and host. A thorough understanding of the 41 
immunological balance of malaria and its relation to other physiological balances in the body is of crucial 42 
importance for developing effective interventions to reduce malaria-related morbidity and to diminish 43 
fatal outcomes due to severe complications. Therefore, we discuss in this review the detailed mechanisms 44 
of antimalarial immunity, parasite virulence factors including immune evasion mechanisms, and 45 
pathogenesis. Furthermore, we propose a comprehensive classification of malaria complications 46 
according to the different types of imbalances. 47 
  48 
3 
 
 49 
1. INTRODUCTION 50 
Malaria remains a major health burden in tropical and subtropical countries. According to the annual 51 
World Malaria Report of the World Health Organization, an estimated 198 million people were clinically 52 
affected by malaria in 2013 and approximately 584 000 of these patients died due to severe 53 
complications. More than 90% of deaths occur on the African continent where mainly children and 54 
pregnant women are a risk of developing life-threatening complications. Adults in high-transmission 55 
areas have acquired semi-immunity against the parasite and are therefore protected against complications, 56 
but often harbor parasites as asymptomatic and transmitting carriers. In low-transmission areas, semi-57 
immunity is less probable to develop and also adults are at risk of severe malaria [1]. Although five 58 
different Plasmodium species are known to infect humans, most of the infections are caused by P. 59 
falciparum and P. vivax. In the last 150 years, important progress was made in the understanding of 60 
malaria, and due to the availability of effective antimalarial drugs, the widespread use of vector control 61 
programs, increased funding and the improved functioning of local health systems, global malaria 62 
mortality rates have decreased by 47% since the year 2000. However, these progresses are challenged due 63 
to the development of resistance against the currently used antimalarial drugs and insecticides, the 64 
presence of asymptomatic but infective carriers, the decreased funding and the increased number of 65 
nonimmune travelers and refugees, and malaria-associated complications remain highly prevalent and 66 
lethal. Furthermore, if we want to further decrease morbidity and mortality or even go onto the path 67 
toward elimination, a better understanding of the mechanisms steering the immunological balance 68 
towards parasite clearance or severe complications is of paramount importance. 69 
 70 
1.1. Multiple balances determine the outcome of malaria infections 71 
Infection is initiated when sporozoites are injected together with anticoagulant saliva during a blood meal 72 
of an infected Anopheles mosquito. Parasites migrate to the liver in search of a favorable niche in the 73 
hepatocyte and successfully replicate in the liver, after which newly formed merozoites are released in the 74 
blood stream. During the blood-stage of the asexual developmental cycle, malaria parasites replicate 75 
inside red blood cells (RBCs). As RBCs are not targeted by cytotoxic cells, the parasite is temporarily 76 
protected from being eliminated. Nevertheless, the immune system is equipped to protect the host against 77 
an ongoing infection. While digesting host hemoglobin (Hb) and replicating inside the RBC, the parasite 78 
expands and changes RBC membrane deformability. Plasmodium falciparum (P. falciparum)-infected 79 
RBCs (iRBCs) become more rigid, whereas P. vivax-infected cells become more flexible [2]. The splenic 80 
macrophage phagocytotic system efficiently removes P. falciparum-iRBCs from the blood stream as they 81 
are not flexible enough to pass through the interendothelial slits of the sinuses [3, 4]. In addition, 82 
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individual merozoites, released into the circulation at schizont rupture, can be recognized by adaptive 83 
immune mechanisms and may be captured before invading new RBCs [5, 6].  84 
The Plasmodium parasite has evolved survival strategies for immune evasion to sustain parasite 85 
replication until sexual gametocytes are picked up by a mosquito, thus supporting malaria transmission. 86 
While growing inside the iRBC, parasite antigens are inserted in the RBC membrane through a 87 
specialized transport system and interact with several adhesion molecules on the endothelial lining of the 88 
peripheral microvasculature [7, 8]. This phenomenon, which is called sequestration, retains the iRBCs 89 
containing the more mature forms (i.e. trophozoites and schizonts) in different organs such as lungs, 90 
brain, placenta, intestinal tract, spleen, bone marrow and adipose tissue, to evade the splenic sieving 91 
machinery. Furthermore, sequestration may contribute to create a metabolically favorable niche, or even 92 
to facilitate invasion as is suggested for reticulocyte-restricted parasites [9]. Because of these surface 93 
parasite adhesins, the iRBCs are no longer ‘invisible’ for the adaptive immune system and become the 94 
target of specific antibodies (Abs). To circumvent these adaptive immune mechanisms, the cell-surface 95 
proteins are subjected to antigenic variation, i.e. the parasite switches to other adhesin variants on the 96 
iRBC membrane and temporarily escapes the immune systems’ vigilance. This is translated in wave-like 97 
parasitemia courses and recrudescences [10]. Furthermore, a high diversity of exposed proteins between 98 
isolates and the release of immunomodulatory parasite molecules in the circulation during schizont 99 
rupture further contribute to the inability of the host to mount sterile immunity.  100 
The interplay between antiparasite immunity elicited by the host and virulence mechanisms of the parasite 101 
in some cases leads to severe pathology. A thorough understanding of the balance between the two 102 
systems is of crucial importance. Additional balances, i.e. metabolic, erythropoietic and vascular 103 
balances, may further complicate the outcome of infections (Figure 1). Therefore, we generated an 104 
extensive overview of the current knowledge about antiparasite immunity, parasite virulence factors 105 
resulting in immunomodulation or immune evasion, and pathological processes, after having considered 106 
some important aspects of parasite and host coevolution. Immune mechanisms are also activated during 107 
the liver stage of the disease, but since only asexual blood-stage parasites contribute to disease symptoms, 108 
we will only discuss the mechanisms related to the asexual erythroid development of the parasite. 109 
However, it should be kept in mind that the initial load of merozoites coming out of the liver might have 110 
an impact on the generation of immune responses and the subsequent (im)balances. 111 
 112 
1.2. Evolution leads to a fine balance between parasite growth and immune control 113 
Parasites take profit of their host by utilizing them as a food source, for protection against the 114 
environment and for transmission and spreading. In general, parasite virulence and high parasite densities 115 
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within a host are positively associated with increased transmission [11]. Excessive virulence rapidly kills 116 
the host and results in abrogation of parasite transmission. As a consequence, parasite virulence evolves 117 
according to this trade-off to an optimum with an ‘intermediate’ virulence. Since parasites evolve rapidly 118 
and adapt to changes in host or environment in only a few decades, partial immunity or the use of non-119 
sterilizing vaccines may select for parasites with higher virulence in non-immune or non-vaccinated 120 
people [12, 13]. For malaria, this may also be applicable but it is further complicated by the fact that 121 
transmission is ensured by gametocytes, whereas virulence and pathology are more related to the asexual 122 
blood-stages. The asexual blood-stages are crucial to generate gametocytes, which do not multiply but 123 
may remain in the circulation for several weeks and may continue their life cycle when taken up by 124 
mosquitoes. The complex biology of gametocytes, the factors influencing the asexual stage-to-gametocyte 125 
conversion, the gametocyte prevalence and transmission to mosquitos are subject to intense research and 126 
have been reviewed [14].  127 
The host is also evolving under selective pressure by parasites towards minimization of host damage, 128 
albeit a broader timescale is needed to induce these adaptive changes. Evidence that malaria is exerting 129 
substantial selective pressure on the human genome is provided by the multiple polymorphisms in genes 130 
encoding for RBC proteins [15, 16]. Some polymorphisms are harmful for the host but are maintained in 131 
the human population in malaria-endemic regions because of the partial resistance they provide against 132 
malaria. Some good examples of this are the sickle cell and thalassemia gene mutations in the genes 133 
encoding Hb. Furthermore, immune mechanisms to clear parasites are counterbalanced by immune 134 
evasion mechanisms of the parasite and, therefore, tolerance may appear, i.e. the ability of the host to 135 
minimize virulence without necessarily decreasing parasite density [17]. In turn, evolution to tolerance in 136 
the host results in a shift of the virulence trade-off optimum and may select for parasites with higher 137 
within-host densities and transmission. A certain level of tolerance to malaria parasites is evidenced by 138 
the higher pyrogenic threshold in adults [18]. Ultimately, coevolution may lead to harmless 139 
commensalism. This requires a delicate balance between a robust but tightly controlled immune response 140 
elicited by the host to eliminate the parasites without causing collateral damage and mechanisms used by 141 
the parasite to modulate or evade this immune response. Imbalances, i.e. insufficient immunity resulting 142 
in exaggerated parasite growth, exaggerated immune reactions and inflammation, or both, are harmful and 143 
in some patients may even lead to life-threatening complications. Throughout this review, this 144 
equilibrium will be referred to as the immunological balance (Figure 2A). 145 
Malaria parasites presumably did not simply coevolve and differentiate together with their hosts, but 146 
rather appeared later in the evolution and spread to different hosts, including humans, by host switches 147 
[19]. This might in part explain the considerable disease burden by malaria in the human population. The 148 
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most plausible scenario for the origin of P. falciparum, which causes the greatest malaria burden in 149 
humans, is that it originates from gorillas [20], even if P. falciparum (-like) strains have also been 150 
detected in other primates [21-23]. Similarly, parasites closely related or identical to P. vivax, P. ovale 151 
and P. malariae have been identified in wild-living chimpanzees [20, 24]. The origin of P. vivax is most 152 
probably in African apes from where it spread to humans over the continents. Later, it disappeared from 153 
the human African population, most probably due to counterselection by the widespread Duffy-negative 154 
phenotype [25]. Analysis of the sequence diversity between different isolates suggests that P. falciparum 155 
appeared more recently in humans than P. vivax, a parasite which in general is less virulent than P. 156 
falciparum [26]. Furthermore, tolerance evolution in the main host, and a concomitant shift towards 157 
higher intrinsic virulence of a parasite, may explain the higher virulence of a parasite in non-adapted 158 
hosts, as is observed for severe zoonotic diseases [17]. This is illustrated by P. knowlesi-infections, which 159 
result from zoonotic transmission from macaques to humans in Southeast Asia and often cause severe 160 
disease [27]. 161 
The immunological balance is further complicated by genetic variations in both host and parasite, by the 162 
hosts’ nutritional status, by additional infections with other microorganisms, and by the polyclonality of 163 
Plasmodium infections. When several parasite (sub)strains are present in a single host, competition for 164 
space and nutrients results in positive selection of more virulent strains, as has been shown experimentally 165 
in animal models [28]. In a population, high transmission is supposed to result in a high complexity of 166 
infection (polyclonality), leading to increased recombinations during the sexual phase in the mosquito 167 
[29]. Adaptive immune pressure by the host selects for low-frequency alleles in immune-exposed genes 168 
of the parasite and negatively selects against high frequency alleles, a process called balancing selection 169 
[30]. Such balancing selection prevents both fixation and loss of alleles and, therefore, leads to a high 170 
genetic diversity within the parasite population. Duplication of genes has generated multigene families 171 
displaying antigenic variation by differential expression and allelic exclusion, such as the var multigene 172 
family encoding P. falciparum erythrocyte membrane protein-1 (PfEMP-1), the main mediator of 173 
cytoadherence and parasite sequestration [31]. The expression of these antigenic variant genes is also an 174 
important determinant for immune evasion and pathology and greatly influences the immunological 175 
balance. 176 
A striking parallel example of this immunological balance is the disease course elicited by the three 177 
different genotypes of Toxoplasma (T.) gondii in mice, which match the three different outcomes of the 178 
immunological balance and of which the molecular basis has been elucidated in great detail [32]. T. 179 
gondii type 1 parasites induce an anti-inflammatory response and evade intracellular killing, resulting in 180 
death by hyperproliferation of the parasite. In contrast, T. gondii type 2 parasites rather induce an 181 
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exaggerated T-helper (Th)1 response resulting in immunopathology. Type 3 T. gondii activates anti-182 
inflammatory signaling, does not evade intracellular killing, and is able to establish persistent and latent 183 
infections in mice.  184 
As will be detailed below, in malaria, the immunological balance may also be tilted to one or the other 185 
side, depending on the host and parasite species and strain. In addition, the combination of high parasite 186 
burden and exaggerated immunopathology may also occur. Thus, it will be a challenge to eradicate a 187 
parasite with an evolutionary lifespan going back far beyond the origin of man and that has acquired 188 
several survival strategies and selected for protective genetic polymorphisms in the host in a process of 189 
coevolution.  190 
 191 
1.3. Literature database and role of mouse models in malaria research 192 
Defining the immunological balance in malaria patients is a major challenge. Because of concomitant 193 
inflammation and metabolic disturbances, it is difficult to discriminate between the different types of 194 
imbalances, i.e. insufficient immunity and/or excessive immune evasion promoting parasite replication, 195 
exaggerated inflammation resulting in immunopathology, or the combination of excessive immune 196 
evasion and exaggerated inflammation (Figure 2A). In patients, this is further complicated by genetic 197 
variation, environmental factors and therapeutic interventions. As such, mouse models of malaria have 198 
provided crucial insights in molecular events dictating these balances, because of inherent technical 199 
possibilities that are not available in clinical studies for ethical reasons. For example, with the use of 200 
inbred strains of mice it is possible to exclude genetic differences and, by microbiome monitoring, 201 
specific coinfections may be excluded. In human studies, this is not possible. Hitherto, commonly used 202 
methods to investigate immunological balances are mouse models with rodent malaria parasites (P. 203 
berghei, P. chabaudi, P. yoelii and, to a lesser extent, P. vinckei). The natural hosts of these parasites are 204 
African tree rats (Grammomys surdaster and Thamnomys rutilans) and these parasites are 205 
phylogenetically somewhat more related to P. vivax, P. ovale, P. malariae and P. knowlesi than to the 206 
Laverania, the Plasmodium subgenus that includes P. falciparum [33, 34]. Rodent and human malaria 207 
species are different and, therefore, experimental malaria infections in rodents are not perfect models of 208 
human malaria. For example, the acquisition of immunity in mouse models of malaria may already occur 209 
after a single infection, whereas this may not be the case in humans due to the high diversity of the 210 
different circulating (sub)strains. Nevertheless, mouse models are excellent tools to dissect the molecular 211 
details of the immunological balance and provide the possibility of testing interventions to restore 212 
imbalances. When extrapolating such data to possible treatments for patients, it is of crucial importance to 213 
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understand the immunological (im)balances in both animal models and in patients to avoid 214 
misinterpretation and adverse outcomes in clinical trials.  215 
Extensive data are available in the literature on the molecular immunology of malaria, both from clinical 216 
and rodent studies. To generate a complete overview, we constructed a database containing over 2450 217 
entries from more than 500 PubMed publications (www.malarimdb.org). The practical use of this 218 
database has been discussed in detail [35]. In this database, levels of diverse immunological factors are 219 
schematically compared in patients with different degrees and complications of malaria, and also 220 
expression data and experimental treatments or knockout studies in mouse models are included. The 221 
database is fully searchable and allows the comparison of patient and mouse data. The main insights from 222 
this database form the basis for the construction of this manuscript. 223 
 224 
2. Antiparasite immunity 225 
Upon a primary infection, an immune response is generated in which the spleen plays a central role [4, 226 
36]. Innate immune mechanisms are first activated and limit the acute phase of parasitemia but are not 227 
able to clear the infection. Adaptive immunity is activated when dendritic cells (DCs) present processed 228 
antigens to naïve T cells. Activated T cells then provide help to Ab-producing cells. Eventually, the 229 
infection may be cleared from the circulation by Ab-mediated immunity directed against specific parasite 230 
antigens, unless immune evasion mechanisms by the Plasmodium parasite provide sufficient 231 
counterbalance against immune clearance. In this section, we discuss the mechanisms of antiparasite 232 
immunity. In section 3, the parasitic virulence factors and immune evasion mechanisms which interfere 233 
with the generation of efficient antiparasite immunity will be detailed, and section 4 is an extensive 234 
overview of how imbalances result in severe pathology. The influence of immunoregulatory mechanisms, 235 
elicited by the parasite or mounted by the host to counter inflammation, dampen inflammatory damage 236 
but also antiparasite immunity and these have therefore a crucial influence on the immunological balance 237 
between parasite and host (see section 5). Based on these insights, we attempt to classify the various 238 
outcomes and complications according to this balance in section 6 and summarized this in Figure 2 239 
(panels B and C).  240 
2.1. Direct killing mechanisms in malaria 241 
In this section, the direct effector mechanisms which remove the pathogen from the circulation will be 242 
discussed, i.e. phagocytosis, complement, antibodies and cytotoxicity. Section 2.2 will cover indirect 243 
mechanisms that govern, improve and specify the effector functions. This includes cytokine production, 244 
antigen presentation to activate CD4+ T cells and B cell activation. 245 
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2.1.1. Phagocytosis 246 
Phagocytosis is a process by which foreign antigens or particles such as iRBCs, free merozoites, and 247 
hemozoin (Hz) are recognized, captured, internalized and neutralized by specialized cells of the immune 248 
system like monocytes, macrophages, polymorphonuclear granulocytes (PMNs) or DCs. It plays an 249 
essential role in parasite clearance [5, 37-40]. Phagocytic removal of malaria parasites predominantly 250 
occurs by macrophages in spleen and liver, as witnessed by the large amount of pigment found in these 251 
organs [41-43]. During an acute malaria infection, monocytes are massively recruited from the bone 252 
marrow, and contribute, in addition to local proliferation, to the hepatosplenomegaly so typically 253 
observed in malaria patients and mice [41, 44]. Once infiltrated in the tissues, these monocytes 254 
differentiate into macrophages or DCs, and augment the organs’ phagocytic and antigen presentation 255 
capacity. In between bone marrow and the target organs, monocytes travel through the peripheral 256 
circulation. Depending on the maturation status, different blood monocyte subsets can be distinguished, 257 
which differ in their cytokine secretion and their capability to phagocytose merozoites, iRBCs and/or 258 
pigment. For example, the CD14hiCD16/Fc receptor (FcR) IIIA+ ‘inflammatory’ or intermediate 259 
monocyte subset, followed by the more mature ‘macrophage-like’ CD14loCD16/FcRIIIA+ subset, seem 260 
to be the monocyte subtypes primarily equipped for phagocytosis of P. vivax-infected cells in vitro [45]. 261 
In P. falciparum-infected children, the expression level of CD16/FcRIIIA on these two subsets correlates 262 
with tumor necrosis factor (TNF) production and in case of the more mature CD14loCD16/FcRIIIA+ 263 
subset, a negative correlation was found with Hb levels, thereby suggesting a role in erythrophagocytosis 264 
[46]. 265 
Phagocytosis is initiated when pathogen-associated molecular patterns (PAMPs) of parasitic origin 266 
interact with pattern-recognition receptors (PRRs) on the host cell surface. Parasite antigens interact with 267 
a wide range of different receptors, and the relative importance of particular receptors changes during the 268 
course of infection. In the early phase of antimalarial immunity, the scavenger receptor CD36 seems to be 269 
the main receptor involved in parasite removal, both in humans and in mouse models [47-50] (Figure 3). 270 
Interaction between parasite-derived products and Toll-like receptors (TLRs) or mannose receptors have 271 
also been described [51-53], but might be more important for the subsequent signaling they induce than 272 
for parasite removal per se [47, 53-57]. Furthermore, the complement system is activated and produces 273 
soluble complement factors that can act as opsonins. When complement-bound parasite antigens interact 274 
with complement receptors (CRs) on phagocytes, they are subsequently phagocytosed [40, 58]. As the 275 
adaptive immune system is not yet fully active, parasite replication exceeds parasite clearance, and thus 276 
the initial phase of a blood-stage malaria infection is one of increasing asexual parasitemia. Later during 277 
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the infection, specific Abs are secreted that also act as opsonins and mediate phagocytosis via binding to 278 
FcRs [58-60]. Opsonophagocytosis mediated by Abs is antigen-specific and accelerates the interaction 279 
between free merozoites or iRBCs and phagocytes and reduces peripheral parasitemia.  280 
Once the parasite is bound to the phagocyte, the receptor-parasite complex is internalized by an actin-281 
dependent process [39]. The phagosome fuses with lysosomes to form a phagolysosome with an acidic 282 
pH that is ideally suited for protein complex dissociation and degradation by acidic proteases [61]. Except 283 
for Hz, the crystalline waste product of Hb consumption which remains intact inside the phagocyte, all 284 
parasite constituents are efficiently degraded and the used receptors are recycled. Depending on the type 285 
of receptor used for binding and internalization, phagocyte activation is triggered and translated in an 286 
increased expression of FcRs and CRs, generation of a respiratory burst and secretion of proteolytic 287 
enzymes and cytokines [40, 53, 62, 63]. Cytokines orchestrate the antiparasite immune response but are 288 
also involved in severe pathology (see further). Reactive oxygen species (ROS) and reactive nitrogen 289 
intermediates (RNI) produced during the respiratory burst are cytotoxic for the internalized parasites and 290 
can cross the cell membrane to cause damage to merozoites and iRBCs that are in close proximity to the 291 
monocyte/macrophage [64]. Free radicals generated by the xanthine oxidase/hydrogen peroxide system 292 
and NADPH oxidase in combination with inducible nitric oxide synthase (iNOS), seem to be primarily 293 
involved in inducing the degeneration of intraerythrocytic parasites into crisis forms [45, 64-66]. PMN 294 
activity against adherent parasites has also been demonstrated, but seems to be ROS-independent [67, 68].  295 
2.1.2. Activation of the complement system 296 
The complement system is activated early during infection. Mannan-binding lectin (MBL), an acute-297 
phase protein produced by the liver, can activate the complement system through the lectin pathway and 298 
has been shown to bind carbohydrate structures on iRBCs [69, 70]. Ab-parasite-complexes can activate 299 
the classical pathway. In particular, Ab-mediated fixation of complement on merozoites results in the 300 
formation of the membrane attack complex and this plays a major role in the Ab-mediated inhibition of 301 
invasion [71]. Free digestive vacuoles containing Hz and band 3 receptor clustering can trigger alternative 302 
complement pathway activation [72-74]. Both senescent and malaria-infected erythrocytes suffer from 303 
increased oxidative insults. This results in increased hemichrome deposition and promotes band 3 304 
receptor clustering on the RBC membrane. In this way, new epitopes are exposed, recognized by 305 
naturally-occurring anti-band 3 auto-Abs with subsequent C3b deposition, and these C3b-coated immune 306 
complexes (ICs) are recognized by CR1 (CD35) resulting in erythrophagocytosis. Increased levels of anti-307 
band 3 class G Immunoglobulins (IgGs) are detected in serum of P. falciparum-infected children [75, 76]. 308 
This type of phagocytosis is accelerated in the presence of underlying erythrocyte disorders such as sickle 309 
cell trait, beta-thalassemia, glucose-6-phosphate dehydrogenase (G6PDH) deficiency, and pyruvate kinase 310 
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deficiency [77]. Furthermore, it is influenced by the ABO phenotype and might in part explain the 311 
predominance of blood group O in malaria-endemic regions. Hemichrome formation and band 3 312 
aggregation is increased in ring and mature-stage infected O-type RBCs compared to A or B type RBCs, 313 
and O type iRBCs are more avidly phagocytosed [78].  314 
Besides phagocytosis, complement-mediated lysis may also occur. iRBCs are relatively resistant towards 315 
complement-dependent lysis by the presence of complement regulatory proteins on the plasma membrane 316 
of human iRBCs [e.g. CR1, decay accelerating factor (DAF or CD55) and protectin (or membrane 317 
inhibitor of reactive lysis (MIRL) or CD59)] [79, 80]. This can be circumvented by binding of C-reactive 318 
protein (CRP), an acute-phase protein that is increased in plasma of malaria-infected patients, to the red 319 
cell membrane [80-83]. CRP binds to the surface of apoptotic cells, and phosphatidylserine (PS) 320 
exposure, a characteristic feature of apoptotic cells, has been observed on the outer surface of iRBCs [84-321 
86]. The interaction between CRP and RBCs decreases the expression and the affinity of complement-322 
regulatory proteins and favors complement-deposition [80].  323 
The precise strategy how the complement system acts during antimalarial immunity i.e. by 324 
opsonophagocytosis or complement-dependent lysis, has not yet been fully clarified. In general, however, 325 
the complement system seems to play only a minor role in the resolution of a primary infection because 326 
even in the absence of complement, parasites are cleared from the circulation [87, 88]. In contrast, 327 
exaggerated complement activation has been observed in severe malaria patients and contributes 328 
significantly to pathology, including the promotion of inflammation and anemia [75, 89, 90]. 329 
Furthermore, the terminal part of the complement pathway is activated in mice with cerebral malaria 330 
(CM) as illustrated by increased C5 levels and C9 deposition in mouse CM brains [91, 92], and 331 
deposition of C3d and the assembled C5b-9 complex on sequestering RBCs in brain sections of patients 332 
who died from CM [90].  333 
CR1 has multiple roles in malaria, both beneficial and pathogenic. Besides mediating the removal of 334 
complement-decorated senescent and iRBCs, it is the main receptor involved in clearance of circulating 335 
ICs. If not removed, ICs accumulate in the circulation and in the kidney with glomerulonephritis as a 336 
result. Circulating ICs can interact with CD16/FcRIII resulting in phagocyte activation and augmentation 337 
of the inflammatory response. Both in patients and in mice with malaria, CR1 surface expression is 338 
reduced on monocytes, macrophages, and B cells (but not on PMNs) resulting in increased levels of 339 
circulating ICs [93]. Furthermore, by the presence of CR1 on the surface of human RBCs, RBCs 340 
participate in IC clearance by transferring CR1-bound ICs to phagocytic cells [93]. In this process, CR1 is 341 
lost from the red cell membrane. Since CR1 protects the red cell against complement deposition, this 342 
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mechanism can promote complement-mediated lysis of both infected and uninfected RBCs, and 343 
contribute to anemia (see section 4.2.5). CR1 and DAF/CD55 are also used by P. falciparum-merozoites 344 
to invade erythrocytes [94-96], and CR1 is also involved in immune evasion by mediating rosette 345 
formation of P. falciparum-iRBCs, i.e. clustering of iRBCs with uninfected RBCs [97] (see also section 346 
3.3.1.2). Murine erythrocytes do not have CR1 but instead express a CR1-like molecule, Crry, which does 347 
not participate in clearance of circulating ICs [98]. 348 
2.1.3. Antibodies 349 
During a primary infection, Ab-independent immune mechanisms are often able to limit the severity of 350 
infection. However, for complete parasite clearance, Ab-dependent immunity is indispensable as 351 
illustrated by the following observations. Malaria-infected B cell-deficient mice develop a low chronic 352 
parasitemia with higher recrudescences [99-103]. This B cell-deficiency may be compensated by an 353 
expansion of T cells, but, if the latter are also depleted, a high parasitemia persists [104, 105]. Antigen 354 
variation may occur with parasite antigens under high Ab pressure (see section 3.2.2). Therefore, the 355 
repertoire of specific Abs is broadened with subsequent Plasmodium infections [106]. The initial Ab 356 
repertoire may presumably protect against severe disease and broadened Ab repertoires are necessary 357 
against symptomatic infection and are a prerequisite for developing semi-immunity or premunition in 358 
malaria-endemic regions [[107, 108] and reviewed in [1, 109, 110]]. Passive transfer of purified IgGs 359 
from semi-immune people or from semi-immune mice (partially) suppresses peripheral blood parasitemia 360 
and symptoms as rapidly as antimalarial drugs [59, 111-113]. 361 
The isotype of antibodies produced does not only depend on the mode of B cell activation, e.g. 362 
extrafollicular or in germinal centers (GCs) (see section 2.2.3), but also on the inflammatory environment 363 
surrounding the B cell subsets. The proinflammatory Th1-type environment during malaria infection will 364 
predominantly stimulate isotype switching to cytophilic or opsonizing Abs such as IgG1 and IgG3 in 365 
humans or IgG2a and IgG2b in mice, which will be of main importance for controlling the infection 366 
through several mechanisms [114, 115], some of which are outlined here. Abs against merozoite proteins 367 
involved in RBC invasion, including merozoite surface protein-1 (MSP-1), apical membrane antigen-1 368 
(AMA-1), and erythrocyte-binding antigen-175 (EBA-175), have been documented in sera from P. 369 
falciparum-infected individuals [116-119]. Invasion-inhibitory Abs recognizing P. falciparum 370 
reticulocyte-binding-homologue-4 (PfRh4) or P. vivax Duffy-binding protein (PvDBP) correlated with 371 
protection against P. falciparum and P. vivax infections, respectively, in individuals from Papua New 372 
Guinea [120, 121]. Ab-mediated opsonic phagocytosis of merozoites correlates with protection from 373 
clinical episodes and high-density parasitemia in P. falciparum-infected children from Papua New Guinea 374 
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and Africa [122, 123]. Furthermore, Abs on merozoites activate the classical complement pathway, which 375 
triggers merozoite lysis, and this appears to be the most efficient mechanism for blocking reinvasion [71]. 376 
Once RBC invasion is successful, the parasite resides inside a protective parasitophorous vacuole shielded 377 
from the host cell cytoplasm. During maturation, the parasite exports parasite-encoded proteins to the 378 
iRBC membrane that enables the parasite to evade specific immune mechanisms (see section 3.3). Abs 379 
against these parasite proteins are involved in opsonic phagocytosis of iRBCs and interfere with 380 
endothelial cytoadherence, and/or mediate rosetting [5, 124-127]. Furthermore, inhibition of parasite 381 
growth by entering of Abs inside the iRBC has been described and may be enhanced by monocytes in a 382 
process of Ab-dependent cellular inhibition mediated by FcRII and TNF [128, 129]. 383 
The malaria parasite has developed multiple strategies to interfere with and evade Ab-mediated immunity. 384 
These strategies include antigen variation and antigen diversity (section 3.3.2), and modulation of B cell 385 
maturation and the memory compartment (section 5.5). Consequently, with P. falciparum infections this 386 
type of immunity wanes rapidly and the acquisition of parasite-specific memory B cells (MBCs) and 387 
long-lived Ab-secreting cells is inefficient and slow [106, 130]. 388 
 389 
 2.1.4. Cell-dependent cytotoxicity 390 
Direct cell cytotoxicity can contribute to remove pathogens from the host in various infectious diseases. 391 
However, whether and to what extent this mechanism is also involved in the antimalarial response is not 392 
yet fully clear. Mature RBCs have lost the ability to express major histocompatibility complex (MHC) 393 
class I molecules and as a consequence are not subjected to CD8+ T cell-mediated cytotoxicity. Several 394 
Plasmodium species, including P. vivax and particular strains of P. yoelii and P. berghei, preferentially 395 
infect reticulocytes above normocytes (see section 3.1). Reticulocytes express MHC class I molecules on 396 
their surface [131], but even in this case, MHC class I-dependent cytotoxicity by CD8+ T cells does not 397 
seem to contribute to clearance of infected cells [132, 133]. Nevertheless, parasite-specific cytotoxic T 398 
lymphocytes (CTLs) are activated during malaria infection and contribute to the overall antiparasite 399 
response, both in the acute and in the chronic phase [134-138]. Their importance could be masked by the 400 
influence of the inhibitory programmed death-1 (PD-1) receptor, which seems to reduce considerably 401 
CD8+ T cell numbers and functionality during malaria [136]. How CTLs contribute to parasite clearance 402 
remains elusive in the absence of MHC class I. Infection of erythroblasts, erythroid precursor cells, has 403 
been shown in vitro with P. falciparum and in vivo in the bone marrow of two P. vivax-infected but 404 
aparasitemic patients and also in P. yoelii-infected mouse spleens [138-141]. Erythroblasts express high 405 
levels of MHC class I and Fas, a receptor involved in apoptosis. Indirect killing of infected erythroblasts 406 
is suggested to occur through Fas-Fas ligand (FasL) interaction [138]. This results in PS disposure on the 407 
outer membrane of the cell, and accelerates engulfment of the apoptotic cell by phagocytes, possibly 408 
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mediated through T cell immunoglobulin-domain and mucin-domain-containing molecule 4 (Tim-4). The 409 
importance of this mechanism for parasite clearance seems limited, since even if erythroblasts are 410 
infected, their percentage is very small compared to infected erythrocytes and reticulocytes, which 411 
generally do not express Fas. This process can, however, contribute to ineffective erythropoiesis and may 412 
predispose to anemia. 413 
Platelets most probably contribute to parasite clearance. Human and murine platelets secrete platelet 414 
factor 4 (PF4/CXCL4) from intracellular α-granules upon platelet activation. After binding to and 415 
internalization by the Duffy-Ag receptor (DARC/Fy/CD234) on iRBCs, the digestive vacuole of the 416 
parasite is lysed. This results in intraerythrocytic parasite killing and limits parasite replication before 417 
adaptive immunity is activated [142, 143]. These data implicate that drugs that inhibit platelet activation 418 
such as aspirin, which is often used before admission to the hospital, have potentially harmful effects 419 
during malarial infections [144]. Thrombocytopenia, which is reported in a large percentage of malaria 420 
patients, may also negatively influence this type of parasite clearance [145]. Furthermore, platelet-421 
mediated killing is abrogated in DARC-deficient RBCs, indicating that this mode of protection against 422 
malaria may be absent in the vast majority of African inhabitants who are Duffy-negative and who suffer 423 
from the highest mortality rates due to P. falciparum malaria [142].  424 
Natural killer (NK) cells are also activated during malaria. However, in mice, NK cells mainly contribute 425 
to the early resistance against a blood-stage infection by their cytokine secretion rather than their 426 
cytotoxicity (see section 2.2) [146, 147]. In humans, both mechanisms may contribute, since human NK 427 
cells are cytotoxic for P. falciparum-iRBCs in vitro (although contradictory data exist) [148-153], an 428 
effect that was dependent on granzyme B and Fas [151]. Recent data from immune cell-optimized 429 
humanized (RICH) mice now confirm the involvement of NK cell cytotoxicity for the control of P. 430 
falciparum parasitemia, an effect that was dependent on lymphocyte function-associated antigen-1 (LFA-431 
1) and partly also on DNAX Accessory Molecule-1 (DNAM-1/CD226) [154].  432 
The T cell subset may also inhibit P. falciparum-iRBC growth in vitro by killing free merozoites, an 433 
effect that seems to depend on granulysin [132, 155].  434 
2.2. Immunological support mechanisms  435 
Several mechanisms indirectly contribute to the removal of parasites from the blood. Cytokines are 436 
secreted by many different cells of the immune system and regulate the type and intensity of the host 437 
immune response (Figure 3). Early in the course of infection, when adaptive immunity is not yet 438 
activated, mainly phagocytes, NK cells, endothelial cells (ECs), T and  NKT cells produce cytokines 439 
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to augment the required inflammatory response. Later, when specific  CD4 T helper (Th) cells and  440 
NKT cells are present, this response is down- or up-regulated, depending on the polarization of the Th 441 
cell subsets present, and highly specific Ab-producing B cells are boosted. For the successful generation 442 
of the latter processes, optimal function of the splenic white pulp is of major importance, since the white 443 
pulp is the site where cells of the innate and adaptive immune system interact during malaria, and thus 444 
where the generated immune response is improved and specialized [36]. Disorganisation of the splenic 445 
architecture may therefore disturb antimalarial immunity and is discussed in more detail in section 5.5.  446 
2.2.1. Cytokines orchestrate immune cell homeostasis and effector functions 447 
Chemokines, cytokines and their respective receptors contribute significantly to the recruitment and 448 
activation of different cell types of the immune system and augment the phagocytic response. For optimal 449 
clearance of merozoites and freely circulating and sequestering iRBCs, sufficient phagocytes must be 450 
available in the circulation, spleen, liver, bone marrow and placenta, i.e. all organs where active 451 
phagocytosis occurs. Furthermore, adequate numbers of viable and activated DCs must be present in the 452 
spleen and other secondary lymphoid organs to stimulate adaptive cellular and humoral immune 453 
responses. Granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage (GM)-CSF in 454 
combination with interleukin-3 (IL-3) stimulate the proliferation and differentiation of myeloid precursors 455 
in the bone marrow [156-158]. Fms-related tyrosine kinase 3 ligand (Flt3L) produced by mast cells in 456 
response to uric acid release by iRBCs further augments bone marrow myelopoiesis [159]. The newly 457 
produced bone marrow-derived mononuclear cells are recruited to the circulation in a CC chemokine 458 
receptor 2 (CCR2)-dependent or independent way and fuel the phagocytic and antigen-presenting 459 
capacity of the spleen by increasing the number of inflammatory monocytes and CD8+ myeloid DCs 460 
(mDCs). This in turn can augment interferon- (IFN-) production by NK cells and CD8+ T cell activation 461 
[159-161]. Also in malaria-infected patients, highest circulating levels of BDCA3+ DCs, the equivalent of 462 
CD8+ mDCs in mice, and activated CD8+ T cells, are found in patients with highest Flt3L levels [159].  463 
Apart from a role in cell recruitment, cytokines also enhance the immune response. For instance, GM-464 
CSF and TNF synergistically increase FcR and CR expression on human neutrophils and, thereby, 465 
stimulate opsonin-dependent phagocytosis [162]. A central role is played by IFN-. Among others, IFN- 466 
induces myelopoiesis in the bone marrow, enhances the respiratory burst and cytokine secretion during 467 
the phagocytic process and, later during infection, IFN- augments the antigen-presenting activity of DCs, 468 
monocyte/macrophages and B cells resulting in activation and intensification of acquired T and B cell 469 
immunity [40, 163-166]. Therefore, Th1-type reactions are crucial to mount efficient antimalarial 470 
immunity. However, IFN- is also involved in severe pathological reactions (section 4.2.3) and 471 
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insufficiently balanced levels of this cytokine may also contribute to inadequate regulation of the B cell 472 
response (section 5.5). 473 
Presence or absence of IFN- secretion by NK cells and  T cells 24 hours after infection seems to 474 
discriminate between self-resolving and lethal Plasmodium infections in mice [146, 167, 168]. These cell 475 
types may also be involved in early IFN- responses in human infections, since in vitro incubation 476 
experiments with P. falciparum-iRBCs and human peripheral blood mononuclear cells (PBMCs) have 477 
indicated that IFN- is rapidly produced by NK cells,  T cells (including  NKT cells) and  T cells, 478 
although the relative contribution of the different cell types varies between individuals [152, 169, 170]. 479 
PfEMP-1 decreases early IFN- responses (but not cytotoxicity) in NK cells,  T cells and  T cells, 480 
indicating that the parasite can modulate early host inflammatory responses [171]. In mice, activated DCs 481 
(and other myeloid-derived cells like monocytes/macrophages) can stimulate IFN- production by NK 482 
cells through direct cell-cell contact and secretion of soluble mediators including IL-12 [161, 172]. 483 
Concomitantly, NK cell-derived IFN- favors IL-12 production by DCs instead of IL-10. This NK cell-484 
mediated induction of IL-12 seems also necessary in CD8+ mDCs for the generation of parasite-specific 485 
CD8+ T cells that are pathogenic in the brain of mice with CM (see section 4.2.3) [173]. IFN- production 486 
by human NK cells depends on IL-2, IL-18 and intercellular adhesion molecule-1 (ICAM-1)/LFA-1 487 
ligation with monocytes/macrophages [153, 174].  488 
Later during peak parasitemia, IFN--producing CD4+ T cells, together with activated NKT cells, will 489 
take over IFN- production from NK and  T cells and will become the major source of IFN- 490 
production in mice. A similar shift is noted for IFN- production in response to P. falciparum-iRBCs, i.e. 491 
the very early response is dominated by NK cells, whereas T cells become increasingly important at later 492 
time points [170]. This mechanism may be seen as a central theme during malaria infections, although 493 
differences may exist for the different parasite strains. For example, in rodent malaria infections with the 494 
nonlethal strain of P. yoelii (17XNL), an innate macrophage-mediated immune response that is 495 
independent of IFN-, NK cells or T cells and dependent on monocytes or macrophages seems to control 496 
the acute infection stage [175].  497 
 498 
2.2.2. Antigen-presenting cells activate T cells and determine their polarisation 499 
Antigen-presenting cells (APCs) provide an important link between innate and adaptive immunity. 500 
Different cell types can present exogenous protein antigens to conventional T cells in a MHC class II 501 
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restricted way (or glycolipid antigens to NKT cells in the context of CD1d). However, mainly DCs 502 
stimulate the differentiation and polarization of naïve T cells into the different Th cell subsets [161]. 503 
Stromal cell-derived factor-1 (SDF-1 or CXCL12) production early during infection supports DC homing 504 
to the splenic compartment and stimulates optimal positioning of DCs for antigen presentation to naïve T 505 
cells [176, 177]. 506 
In murine malaria models, classical or mDCs, but not plasmacytoid DCs (pDCs), seem to determine the 507 
type, magnitude and kinetics of the T cell response [172, 178]. Furthermore, pDCs seem to support the 508 
infection, survival and replication of murine Plasmodium parasites, and these ‘infected’ pDCs are 509 
infectious when transferred to naïve mice [179]. Maturation of immature DCs is shown to occur after 510 
direct cell-cell contact and phagocytosis of schizont-stage iRBCs and results in upregulation of MHC 511 
class II and costimulatory molecules (CD40, CD80 and CD86) and in IL-12 and TNF production [53, 512 
180]. This maturation needs to be perfectly balanced, since a “hypermaturation” phenotype will block DC 513 
function as is shown for lethal malaria infections in mice characterized by high TNF levels [181]. In the 514 
spleen, activated DCs (but not macrophages or B cells) migrate from the marginal zone into the T cell 515 
rich areas and present their processed antigens in a MHC class II context to naïve T cells (Th0) [182]. In 516 
the presence of costimulatory molecules and IL-12, and in the absence of IL-10, a strong proinflammatory 517 
response (Th1) is induced with mainly IFN--producing CD4+ T cells. 518 
The type of DC involved in activating adaptive immune responses in human infections is less clear, since 519 
only circulating DCs can be studied. Patients with uncomplicated P. falciparum or P. vivax infections 520 
have reduced numbers of both mDCs and pDCs and a decreased mDC/pDC ratio in peripheral blood, 521 
whereas immature DCs seem to accumulate. Furthermore, DC viability, maturation and functionality are 522 
impaired [183-186]. The impaired DC response could result from the increased Treg numbers and high 523 
IL-10 levels also observed in these patients. Tregs can alter the balance between circulating mDCs and 524 
pDCs, whereas IL-10 seems to be responsible for DC apoptosis. Nevertheless, in vitro experiments with 525 
P. falciparum indicate that partially activated mDCs are able to induce IFN- production by CD4+ T cells 526 
[186] and, despite inadequate numbers of fully-activated circulating DCs, IFN--producing CD4+ T cells 527 
are observed in P. vivax and P. falciparum infection [187-189]. The regulation and suppression of the 528 
immune response is further discussed in section 5. 529 
Interestingly, also platelets can process and present antigens in the context of MHC class I together with 530 
the necessary costimulatory molecules to promote T cell responses [190]. Vaccination of malaria-infected 531 
mice with in vitro stimulated platelets decreased parasitemia and subsequently protected against CM 532 
[190]. 533 
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2.2.3. Generation of antibody-producing cells 534 
In contrast to monocytes/macrophages that recognize specific motifs, i.e. PAMPS, B cells recognize 535 
specific conformational epitopes. It is a major function of CD4+ T cells to stimulate B cells to produce 536 
Abs which eliminate the malaria parasites through the mechanisms outlined in section 2.1.3. T cell-537 
dependent B cell activation occurs through both direct cell-cell contact and secretion of soluble mediators. 538 
Furthermore, the cytokines produced during infection also direct the magnitude and type of the acute 539 
humoral response.  540 
Upon an encounter between a naïve B cell and its specific antigen, and in the context of extrafollicular T 541 
cell help, the B cell proliferates and differentiates into a short-lived Ab-producing plasma cell (PC) that 542 
secrete the Abs necessary to eliminate the pathogen during the acute infection. These short-lived PCs 543 
undergo apoptosis after a few days or weeks. Upon sustained antigen-specific stimulation with T cell help 544 
in germinal centers (GC), long-lived PCs and MBCs with a high affinity are produced. MBCs can 545 
circulate throughout the body and, when activated in the marginal zone or in GCs during a new attack 546 
with the same pathogen, they rapidly differentiate into Ab-producing PCs. Long-lived PCs travel to the 547 
bone marrow from where they constantly secrete low levels of Abs to form a first line defense during a 548 
second infection [191, 192].  549 
During a GC reaction, interaction with follicular DCs (fDCs) and follicular CD4+ T helper (Tfh) cells 550 
assists in selection of the clones with the highest affinity for the antigen, and only these high affinity B 551 
cell clones undergo class switching and differentiate into Ab-secreting PCs and MBCs. The process of 552 
affinity maturation improves the affinity by which the Ab binds to its antigen and also depends on the 553 
local presence of specific cytokines. In C57BL/6 mice infected with P. chabaudi AS or with P. yoelii 554 
17XNL, IL-21 production by Tfh cells and interaction of IL-21 with its receptor on activated B cells 555 
appear to be crucial for the GC B cell reaction, for the generation of parasite-specific IgGs and to control 556 
parasitemia in the chronic phase of the infection or upon reinfection with the same parasite strain [193]. 557 
Interestingly, excessive IFN- levels may limit survival or differentiation of Tfh cells and thereby impede 558 
GC reactions. Therefore regulation of IFN- by inhibitory coreceptors plays an important role for optimal 559 
GC reactions [194] (see also section 5).  560 
In order for the different B cell subsets to proliferate, differentiate and survive, they require B cell 561 
activating factor (BAFF) (reviewed in [191]). BAFF production is stimulated in activated myeloid cells 562 
such as monocytes and DCs, e.g. by IFN- and IL-10, after which it is exposed on the surface and then 563 
enzymatically cleaved and released as a soluble form. The type of BAFF (membrane-bound or soluble) 564 
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and the receptor used for this BAFF-signalling differs between naïve B cells, PCs and MBCs allowing 565 
them to be differentially stimulated. Both membrane-bound and soluble BAFF are produced early during 566 
human experimental infection and BAFF and BAFF receptor (BAFF-R) levels correlate with B cell 567 
activation [195]. Also in naturally infected children from malaria-endemic regions increased BAFF levels 568 
are observed [196]. However, most children had low expression levels of BAFF-R on peripheral B cells 569 
and only children with high B cell BAFF-R expression maintained parasite-specific IgGs over a few 570 
months time period, indicating the dysregulated BAFF signaling contributes to short-lived Ab responses. 571 
Loss of membrane-bound BAFF by mDCs has also been observed in P. yoelii-infected mice in which it 572 
negatively influenced the survival of differentiating MBCs. The parasite can also modulate this B cell 573 
response, since soluble P. falciparum-Ags and purified Hz can induce BAFF production by monocytes in 574 
vitro and BAFF levels correlate with peripheral parasitemia [195, 197]. Other influences of malaria on B 575 
cell-mediated immunity, resulting in atypical B cells and possibly B cell exhaustion are discussed in 576 
section 5.5.  577 
 578 
3. Parasite virulence factors disturb the immunological balance by modulating or evading the host 579 
immune response 580 
 581 
As discussed in the previous sections, the immune system of the host is well equipped to clear malaria 582 
parasites from the circulation. However, parasite replication results in the production and release of 583 
various parasite and RBC molecules that are immunologically active or even toxic and that modulate the 584 
induced immune response (Figure 4). Furthermore, the parasite has developed specific mechanisms, such 585 
as cytoadherence and antigenic variation and diversity, to evade antimalarial immunity. The interplay 586 
between the immunomodulating factors produced, the extent of immune evasion, and the host immune 587 
system determine the virulence of the infection and whether the immunological balance is in equilibrium 588 
or imbalanced. This section gives an overview of the parasite virulence factors that may interfere with the 589 
antimalarial immune response. 590 
3.1. Intrinsic growth rate and host cell preference 591 
A primary determinant of microbial virulence is the intrinsic growth rate. For blood-stage malaria 592 
parasites, this is determined by the number of merozoites produced per schizont and by the time required 593 
between RBC invasion and schizont rupture. The latter varies considerably between parasite species, i.e. 594 
24h for P. knowlesi and the murine parasite species P. berghei and P. chabaudi; 36-48h for P. 595 
falciparum; 48h for P. vivax and P. ovale and 72h for P. malariae. In patients, this also corresponds to the 596 
cyclic febrile episodes. Parasites often mature and rupture synchronously thereby releasing high amounts 597 
of pyrogenic molecules during a narrow time-window, which triggers the production of endogenous 598 
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pyrogens such as TNF and IL-1β (reviewed in [198]). Cyclic temperature peaks promote intraerythrocytic 599 
growth, but high temperatures may kill the parasite [198]. Therefore, to protect itself from excessive heat, 600 
the parasite transports ring-infected erythrocyte surface antigen (RESA) proteins in the RBC cytoplasm to 601 
stabilize the spectrin tetramers of the RBC [199]. Also the number of merozoites per schizont is species-602 
dependent. P. falciparum-schizonts produce the highest merozoite numbers (n = 16-36) compared to other 603 
species: P. vivax (n = 14-20), P. ovale (n = 6-18) and P. malariae (n = 8-12) [200]. Furthermore, with P. 604 
falciparum and P. vivax, a single erythrocyte can be infected by more than one parasite, although full 605 
parasite development may be hampered by the limited availability of nutrients and space. Maximally 606 
three merozoites may be able to mature asynchronously into schizonts inside a single erythrocyte [201]. 607 
Another major determinant of virulence is erythrocytic host cell preference. Invasion is reticulocyte-608 
restricted for P. vivax, P. ovale and some rodent strains like P. yoelii 17XNL. This severely reduces the 609 
number of host cells available for invasion (typically < 1-2% of all RBCs) and limits parasitemia unless 610 
anemia drives reticulocytosis to higher levels. Moreover, P. vivax and P. yoelii 17XNL preferentially 611 
invade immature CD71hi reticulocytes, whose presence is largely restricted to erythropoietic tissues [202, 612 
203]. P. falciparum, P. knowlesi, particular rodent parasites including P. chabaudi and some strains of P. 613 
yoelii and P. berghei also invade normocytes and, therefore, give rise to higher parasite loads. 614 
The exact mechanism for reticulocyte-restricted tropism is not known. Binding of P. vivax and P. 615 
knowlesi to DARC is mediated by members of the Duffy binding-like family (DBLs), PvDBP and 616 
PkDBPα, respectively, and P. vivax reticulocyte binding proteins (PvRBPs) [204-206]. However, DARC 617 
is also expressed on normocytes and this may therefore not fully explain the reticulocyte-restriction. For a 618 
long time, P. vivax was considered to be restricted to DARC+ individuals, since the near absence of P. 619 
vivax malaria on the African continent coincides with the widespread presence of the Duffy-negative 620 
phenotype. Some P. vivax African hotspots exist, but this is due to the presence of Duffy-positive 621 
individuals. Lately, the incidence of P. vivax-infections is increasing in DARC- individuals, indicating 622 
that parasite virulence mechanisms are evolving slowly toward a DARC-independent reticulocyte 623 
invasion pathway [207, 208]. 624 
Interestingly, variations in parasite invasion molecules also influence host cell preference. For example, in 625 
the rodent malaria strain P. yoelii, each merozoite originating from a single schizont expresses a distinct 626 
variant of the P. yoelii 235-kDa rhoptry protein (PY235) multigene family, one of the reticulocyte binding 627 
protein homologues multigene families, to enable invasion of different erythrocyte subsets [209]. 628 
Notwithstanding, it seems that it is the amount and type of a specific PY235 variant expressed, but not the 629 
total repertoire of PY235 variants present, which determines host cell selection. However, when the most 630 
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abundantly expressed variant is disrupted in a lethal P. yoelii strain, the capacity to bind to mature 631 
erythrocytes is greatly diminished, and as such, also the number of host cells available for infection [210, 632 
211].  633 
3.2. Parasitic immunomodulatory factors 634 
Several factors produced by the parasite or originating from the (rupturing) infected host cell, including 635 
GPI-anchors, Hz, heme, nucleic acids, microparticles (MPs) and exosomes have prominent 636 
immunomodulatory effects and substantially codetermine the type of immunological balance in the host 637 
and thus the outcome of the malaria infection. In this paragraph, the effects of these factors on the 638 
immunological balance are discussed.  639 
3.2.1. Heme 640 
Upon schizont rupture, residual Hb that was not digested by the parasite is released into the circulation. 641 
When insufficient plasma proteins are present to scavenge cell-free Hb, like hemopexin and albumin, Hb 642 
is oxidized into MetHb, which is highly unstable and eventually leads to the release of free heme 643 
(reviewed in [212]). Free heme is toxic and is suggested to play a role in the pathogenesis of murine CM. 644 
Heme in the presence of ROS might mediate blood-brain barrier (BBB) disruption and may cause 645 
neuroinflammation [213]. Furthermore, by activating the inflammasome heme triggers IL-1 production in 646 
macrophages [214]. Heme also downregulates anti-inflammatory mechanisms, by inducing the expression 647 
of Cu/Zn superoxide dismutase (SOD-1) in PBMCs, which inhibits prostaglandin E2 (PGE2) and 648 
transforming growth factor beta (TGF- secretion [215]. This effect is partially mediated by CD14, since 649 
incubation of heme in the presence of anti-CD14 Abs reduces SOD-1 production and increases PGE2, but 650 
not TGF- secretion. Also Hz can inhibit PGE2 secretion in P. falciparum patients [216]. PGE2 is 651 
important to suppress TNF secretion by inhibiting cyclooxygenase-2 (COX-2), and, as such, protects 652 
against exaggerated inflammation. Induction of heme oxygenase-1 (HO-1) results in degradation of heme 653 
and the production of carbon monoxide (CO), which protects the host against cerebral complications by 654 
blocking CD8+ T cell-mediated neuroinflammation [213]. In lethal and nonlethal severe P. vivax malaria, 655 
network interactions are found between TNF and parasitemia, HO-1 and SOD-1 [217]. Furthermore, 656 
heme induces MP shedding from uninfected RBCs in vitro, a process that is inhibited by N-657 
acetylcysteine. This suggests a heme-mediated oxidative stress pathway for the generation of RBC-MPs 658 
[218]. Free Hb may also scavenge nitric oxide (NO) and cause low NO-bioavailability, which contributes 659 
to the pathogenesis of experimental CM [219]. This is further discussed in section 4.1.3.  660 
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3.2.2. Hemozoin  661 
Heme is released during Hb degradation in the food vacuole of the parasite. The released heme generates 662 
oxidative stress in the cell and is thus toxic for the parasite. As a detoxification process, heme molecules 663 
are dimerized and used as building blocks for stacking into a crystal known as malaria pigment or Hz 664 
(reviewed in [220, 221]). Upon schizont rupture, Hz is released into the extracellular environment as a 665 
remnant body, which may still contain the membrane of the food vacuole. In the circulation Hz interacts 666 
with plasma components and several cell types, including ECs, RBCs and phagocytes, before it is rapidly 667 
removed by phagocytosis (reviewed in [222, 223]). These processes may trigger the activation, 668 
upregulation and/or downregulation of specific inflammatory reactions [74, 220, 221, 224]. For example, 669 
complement deposition with subsequent recognition by CRs and interaction between Hz-bound 670 
fibrinogen and TLR4 mediate phagocytosis [52, 74]. The initial contact of Hz with phagocytes can trigger 671 
ROS production. In the cell Hz can activate the nucleotide-binding oligomerization domain (NOD)-like 672 
receptor family pyrin domain-containing 3 (NLRP3) inflammasome resulting in IL-1 production [225, 673 
226], nuclear factor kappa B (NF-kB) signaling to induce the expression of various proinflammatory 674 
cytokines, chemokines, and activation/maturation receptors including TNF, monocyte chemoattractant 675 
protein-1 (MCP-1/CCL2), and CD83, whereas contradictory data exist for TLR9 (reviewed in [221, 676 
223]). Furthermore, purified Hz can induce BAFF production by monocytes in vitro and thereby 677 
modulate B cell subset maturation and survival as discussed in section 2.2.3 [197]. Some of these effects 678 
are induced by the core crystal itself, whereas others are induced by lipoperoxidation products associated 679 
with Hz such as hydroxyeicosatetraenoic acids (HETEs) and 4-hydroxynonenal (4-HNE) formed by lipid 680 
peroxidation of polyunsaturated fatty acids present in membranes.  681 
Depending on the amount of Hz produced, Hz induces inflammation (section 4.2.3) or immune 682 
dysfunction (section 5.4) due to intoxication of phagocytic cells [227, 228]. Local Hz-induced 683 
inflammation strongly correlates with lung and liver pathology in mice [229, 230], and highest Hz 684 
deposition is observed in brain, placenta and bone marrow from severe malaria patients, indicating that 685 
Hz may also be pathogenic in human malaria infections [231-233]. Furthermore, Hz cannot be degraded 686 
and remains inside the body for a long time [229, 234, 235]. Whether ‘stored’ Hz can still influence 687 
phagocyte functions after the infection is cleared is not known. 688 
3.2.3. Glycosylphosphatidylinositol anchors 689 
GPI glycolipids are conserved among all eukaryotic cells and are involved in anchoring membrane 690 
proteins to the plasma membrane. GPIs are abundantly present on Plasmodium parasites, among others on 691 
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the sporozoite and merozoite surface coats and in the schizont cytoplasm, and can be distinguished from 692 
host cell GPIs by their substituents on the lipid and carbohydrate moieties [236]. GPI-anchors are 693 
recognized as endotoxins by the host and induce proinflammatory responses through interaction with 694 
TLR2 (and to a lesser extend with TLR4) in a myeloid differentiation primary response gene 88 695 
(MyD88)-dependent way [51, 237]. GPIs can also be recognized by CD1d-restricted NKT cells and 696 
vaccination against malarial GPI protects mice from severe disease [238, 239]. Furthermore, GPIs induce 697 
the expression of tissue factor (TF) on ECs, which activates the coagulation cascade (see also section 698 
4.2.2) [240]. GPI-anchors are also suggested to play a role in severe anemia, since insertion of synthetic 699 
GPIs into the membrane of noninfected RBCs formed a complex in vitro that was recognized by anti-GPI 700 
IgGs and IgMs of a patient [241].  701 
3.2.4. Uric acid precipitates 702 
Uric acid is generated from hypoxanthine during nucleic acid metabolism. The parasite cannot synthesize 703 
purines de novo and acquires hypoxanthine from the host through specialized transporters [242]. 704 
Although the enzyme required for conversion of hypoxanthine into uric acid is not present in the 705 
Plasmodium parasite, uric acid precipitates do accumulate within the parasitophorous vacuole of P. 706 
falciparum, mainly in mid- and late-stage parasites, and these precipitates are released in the circulation 707 
upon schizont rupture [242, 243]. Furthermore, hypoxanthine may also accumulate in iRBCs and when 708 
large amounts of hypoxanthine are released in the circulation, it may be converted into uric acid and 709 
further into monosodium urate (MSU) crystals [221]. Uric acid is both protective and detrimental, 710 
depending on the cellular localization. In plasma, uric acid scavenges radicals and protects cells from 711 
oxidative damage [244]. In vitro, uric acid, together with ROS released during the conversion of 712 
(hypo)xanthine, stimulates pyrogenic cytokine secretion, e.g. TNF and IL-6, by murine DCs and human 713 
PBMCs, and induces maturation of human DCs by increasing costimulatory expression [243, 245, 246]. 714 
Uric acid precipitates also promote DC expansion and CD8+ T cell activation by triggering the release of 715 
Flt3L by mast cells [159]. Furthermore, due to its highly inflammatory effects, uric acid and its 716 
precipitates may contribute to severe malaria. In P. falciparum-infected Malian children, plasma uric acid 717 
levels increase with disease severity and are positively correlated with markers of inflammation and 718 
endothelial activation [247, 248]. A pathogenic role of uric acid was also suggested for malaria-associated 719 
kidney damage, fever and splenomegaly [244, 247, 249].  720 
3.2.5. Nucleosomes 721 
Together with Hz, GPIs, heme and uric acid, nucleosomes (histone-DNA complexes) are released into the 722 
extracellular environment by the rupturing schizont. Plasmodium-derived nucleosomes are 723 
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immunologically active, since they induce DC maturation and cytokine production in a TLR9-dependent 724 
way [180, 250, 251]. The cell types expressing TLR9 differ between mice and men, and, therefore, both 725 
species may respond differently to plasmodial DNA [252]. In humans, only pDCs and B cells express 726 
TLR9, whereas in mice TLR9 is also expressed by mDCs and macrophages. It is important to note that in 727 
mice, the effects of TLR9 are dependent on the genetic background, and experiments in TLR9-deficient 728 
mice with an insufficiently defined background result in confounding phenotypes [253]. We therefore 729 
advocate that in all such studies the genetic background and the numbers of backcrosses should be 730 
described in detail.  731 
Remarkably, P. falciparum histones can also activate microvascular ECs in vitro, resulting in a Scr-p38 732 
MAPK-dependent induction of IL-8 and other inflammatory mediators, and in endothelial barrier 733 
dysfunction by disruption of junctional proteins [250]. The latter feature might be associated with severe 734 
complications, since increased permeability and disruption of the BBB and the alveolar-capillary 735 
membrane has been shown in CM and malaria-associated acute respiratory distress syndrome (MA-736 
ARDS), respectively (see section 4.2.4). In addition, circulating human and Plasmodium nucleosomes are 737 
associated with disease severity in P. falciparum-infected patients, suggesting a pathogenic role for both 738 
host and parasite-derived histones [250]. 739 
3.2.6. Microparticles and exosomes 740 
MPs and exosomes are extracellular vesicles that are involved in intercellular communication (reviewed 741 
in [254-256]). They differ in their size, formation and composition. MPs are larger than exosomes and are 742 
directly shedded from the plasma membrane through vesiculation during cell activation or during other 743 
processes including senescence and apoptosis. Consequently, MPs are rich in phospholipids and 744 
membrane surface proteins and may carry parasite molecules when produced by iRBCs. MPs derived 745 
from iRBCs are more potent in activating macrophages than iRBCs, an effect mediated by TLR4 and 746 
MyD88-signalling [257]. These circulating MPs are highly associated with CM in both humans and mice 747 
[258-260]. MPs produced by other cell types including ECs, leukocytes and platelets, are also implicated 748 
in malaria pathology but will be discussed later (see section 4.2.3).  749 
Exosomes are smaller than MPs and are of endocytic origin. They are released after fusion of 750 
multivesicular bodies (MVBs) with the plasma membrane for the disposal of cellular material, for 751 
example during the maturation process of reticulocytes. Therefore, exosomes are enriched in intracellular 752 
components such as proteins of the endosomal pathway and microRNAs (reviewed in [261, 262]). iRBCs 753 
also produce exosomes, which are derived from Maurer’s clefts (MCs), since PfPTP2, a MC residing 754 
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protein, is necessary for MC vesicle budding and intercellular communication [263]. P. falciparum-755 
iRBCs use exosomes for intercellular communication as demonstrated in vitro by the transfer of drug-756 
resistance plasmids. This exosome-mediated intercellular communication between P. falciparum-iRBCs 757 
efficiently increased differentiation into gametocytes and may thus be important for transmission to 758 
mosquitos [263, 264]. Furthermore, immunization with purified exosomes isolated from the nonlethal 759 
reticulocyte-prone P. yoelii 17XNL strain, in combination with CpG, is able to elicit IgGs that recognize 760 
P. yoelii-iRBCs and that protect these mice from a lethal infection when challenged with the normocyte-761 
prone 17XL strain of P. yoelii by altering cell tropism to reticulocytes [265]. 762 
3.3. Immune evasion mechanisms 763 
Besides the various factors released during the asexual blood-stage that can modulate the immune 764 
response, Plasmodium parasites have developed mechanisms to actively evade antimalarial immunity, 765 
including cytoadherance and antigenic variation and diversity as will be discussed below.  766 
 767 
3.3.1. Cytoadherence 768 
Cytoadherence is a major immune evasion mechanism and is mediated by variant surface antigens 769 
(VSAs). The presence of VSAs on the surface of the iRBCs allows them to interact with a wide range of 770 
receptors on the microvascular endothelium, uninfected RBCs and platelets, and results in endothelial 771 
cytoadherence, rosette formation and platelet-mediated clumping, respectively.  772 
3.3.1.1. Endothelial cytoadherence and spleen remodeling 773 
In the spleen, a small percentage of blood flows into the open spaces of Billroth, which is devoid of 774 
endothelial lining and which contains a reticular network of fibers and cells together with highly active 775 
macrophages [36]. This slows down the blood flow and facilitates interaction between iRBCs, resident 776 
phagocytes and other patrolling immune cells. When entering the venous circulation, cells need to 777 
squeeze through the interendothelial slits of the sinuses, which traps iRBCs displaying a decreased 778 
deformability. These two mechanisms render the open circulation of the spleen highly capable of 779 
removing parasites. 780 
Endothelial cytoadherence allows iRBCs to sequester in the microvasculature of multiple organs and to 781 
evade passage through the spleen. P. falciparum-iRBCs sequester by interacting with different adhesion 782 
receptors, including CD36, ICAM-1, chondroitin sulphate A (CSA), heparin sulphate (HS), and 783 
endothelial protein C receptor (EPCR) [8, 266, 267]. Which receptor is used by the parasite depends on 784 
the receptor availability in the vascular bed and the VSAs expressed on the iRBC surface. Interestingly, 785 
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some of the receptors utilized for cytoadherence to e.g. ECs are the same as those used by the immune 786 
system for parasite recognition by phagocytes e.g. CD36 (see section 2.1.1) [268]. Microvascular 787 
sequestration of iRBCs is a generalized feature of P. falciparum malaria and occurs mainly through 788 
PfEMP-1. The antigenic variation of PfEMP-1 and the pathological consequences of PfEMP-1-mediated 789 
cytoadhesion are discussed later in this manuscript (see sections 3.2.2 and 4.1). PfEMP-1 molecules are 790 
encoded by the var multigene family and are presented on iRBC membrane protrusions, also known as 791 
knobs, which are formed by intracellular knob-associated histidine rich proteins (KAHRP) (reviewed in 792 
[267]). These proteins associate with cytoskeletal proteins under the erythrocyte membrane such as actin, 793 
spectrin, and ankyrin, and reduce membrane deformability. This stiffness is further increased by the 794 
insertion of other parasitic proteins in the P. falciparum-iRBC membrane, such as subtelomeric variable 795 
open reading frame proteins (STEVORs), members of the Plasmodium interspersed repeat (pir) multigene 796 
superfamily. The stiffness is important to retain the cytoadherent iRBC firmly attached under flow 797 
conditions [269-271]. Both PfEMP-1 and KAHRP have no homologues in other Plasmodium species. In 798 
P. knowlesi, schizont-infected cell agglutination (SICA) antigens encoded by the SICAvar multigene 799 
family are expressed on the iRBC membrane. A proteomic study identified common sequences with 800 
PfEMP-1, suggesting that both protein families might have a common ancestor [272]. 801 
Sequestration of other human and murine malaria parasites is less well documented. P. vivax-iRBCs are 802 
thought to sequester less because all stages can be observed in the peripheral circulation, they lack 803 
PfEMP-1 orthologs and sticky knob structures, and P. vivax infection increases the deformability of 804 
iRBCs. The latter is (partly) attributed to the multiple invaginations observed on the infected red cell 805 
surface, i.e. caveola vesicle complexes containing P. vivax-encoded antigens [2, 202, 273]. Due to this 806 
increased deformability, P. vivax-iRBCs pass easily through the interendothelial slits of the sinuses, 807 
thereby avoiding splenic entrapment. Nevertheless, as with P. falciparum, P. vivax total parasite biomass 808 
is underestimated by peripheral parasitemia levels and is associated with severe disease [274]. 809 
Furthermore, peripheral parasitemia, but not total parasite biomass, is associated with endothelial 810 
activation, suggesting that parasites rather sequester in organs devoid of endothelial lining such as the 811 
open circulation of the spleen and nonvascular parts of the bone marrow. P. vivax-iRBCs are observed in 812 
spleen biopsies taken from splenectomized patients with acute P. vivax infections [275, 276], and possibly 813 
also on lung autopsies from deceased P. vivax patients from the Brazilian Amazon region [275, 277]. 814 
Furthermore, in vitro experiments demonstrated cytoadherence of asexual P. vivax isolates, although to a 815 
variable degree, to microvascular ECs derived from human lungs, simian brains, and to placental 816 
cryosections, whereas conflicting data are found with human umbilical vein ECs [278-282]. Several host 817 
receptors were identified, such as CSA and hyaluronic acid (HA), but not CD36 or thrombospondin. 818 
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Cytoadherence to ICAM-1 is also shown with P. vivax isolates from the Brazilian [278, 281] and 819 
Colombia Amazon [280], but not with Thai isolates [279]. VIR proteins, encoded by the P. vivax 820 
interspersed repeat (vir) genes (reviewed in [283]), seem to be (partly) involved. Vir genes are members 821 
of the pir multigene superfamily, which are present in the different Plasmodium species, since 822 
homologues are found in P. falciparum (rif/stevor), P. knowlesi (kir), P. berghei (bir), P. chabaudi (cir) 823 
and P. yoelii (yir).  824 
Besides immune evasion, adhesion of reticulocyte-restricted parasites may also play another role. During 825 
experimental mouse infection with the nonlethal reticulocyte-prone strain of P. yoelii, the open circulation 826 
temporarily changes into a ‘closed’ circulation due to the formation of a physical barrier in the cords 827 
made out of fibroblasts, and results in trapping of reticulocytes [9]. P. yoelii 17XNL-infected 828 
reticulocytes were found to cytoadhere to these barrier cells. Similarly, at autopsy of a P. vivax patient, 829 
large numbers of P. vivax-iRBCs were observed in the cords of the spleen. Whether they were simply 830 
there because of mechanical trapping or because of active cytoadherence remains to be determined [275, 831 
276]. It was suggested that the trapping of newly formed reticulocytes in the spleen by temporally closing 832 
the circulation, and the cytoadherence of iRBCs to these barrier cells to immobilize the mature-stage 833 
parasites, could create a favorable niche in which merozoites are released into a reticulocyte-rich 834 
environment to enhance invasion [36]. Also sequestration in the bone marrow, another reticulocyte-rich 835 
environment, might favor invasion [202, 273].  836 
Whether pir homologues in other Plasmodium species (kir, bir, cir and yir) also mediate cytoadhesion is 837 
currently unknown. P. chabaudi has been suggested to sequester in lungs and liver, but the parasite 838 
proteins involved in this process remain to be identified [284]. The expression of cir genes is tissue-839 
specific and changes during the course of infection, indicating that CIR proteins are expressed and could 840 
be important for parasite survival [285, 286], but no role for these in cytoadhesion has been shown so far. 841 
P. berghei ANKA-iRBCs sequester in lungs and adipose tissue in a manner that is partially dependent on 842 
CD36 [287], and in the placenta through a yet unknown mechanism [288]. Sequestration in adipose 843 
tissue, and to a lesser extent in the lungs, is mediated by schizont membrane-associated cytoadherence 844 
protein (SMAC), an intracellular protein that is not encoded by the bir or Pb-fam-3 multigene families 845 
[289]. Until now, no protein is found that is encoded by the bir or Pb-fam-1 multigene superfamily, that is 846 
expressed on the outer membrane of the iRBC and that is involved in sequestration [290, 291]. 847 
Furthermore, in vitro, P. berghei ANKA was shown to adhere to murine brain and lung microvascular 848 
ECs under flow conditions by binding to vascular cell adhesion molecule-1 (VCAM-1), and this type of 849 
binding was found to occur less with P. berghei K173, a strain that does not cause CM [292]. 850 
Cytoadherence of the lethal strain of P. yoelii was shown to occur in an ex vivo cytoadherence assay, and 851 
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was mediated by ICAM-1 but not by VCAM-1 [293]. No P. yoelii proteins are identified yet involved in 852 
this cytoadherence.  853 
3.3.1.2. Rosetting 854 
Rosettes are developed when iRBCs bind to uninfected RBCs. This process may be beneficial for the 855 
parasite by shielding epitopes on the iRBC from opsonizing IgGs. Another possible role is to facilitate 856 
merozoite invasion by bringing uninfected RBCs into close proximity of the bursting schizont, and to 857 
protect against invasion-inhibiting Abs [294]. With P. falciparum, both hypotheses seem plausible, and 858 
probably depend on the adhesin variant and the host molecule mediating rosetting. Furthermore, rosetting 859 
contributes to pathology, since higher rosetting frequencies are observed with P. falciparum isolates from 860 
African children with severe disease [295, 296]. Rosette formation occurs in post-capillary venules where 861 
RBC velocities and shear stress are low, and large aggregates can be found at venular junctions [297]. 862 
Since this is also the place where endothelial cytoadherence occurs, both mechanisms contribute to 863 
microvascular obstruction.  864 
The mechanisms involved in P. falciparum rosette formation with asexual parasite stages are well 865 
characterized, and include the interaction between PfEMP-1 and CR1, and the involvement of ABO blood 866 
group antigens [8]. PfEMP-1 interaction with group O antigens through binding with the sialic acid (SA) 867 
moiety of glycophorin A (CD235a) results in the formation of small rosettes, whereas larger rosettes are 868 
formed in the presence of type A RBC by binding of P. falciparum-encoded repetitive interspersed 869 
families of polypeptides (RIFINs) with group A antigens on A-type RBC [298]. In vitro, P. falciparum 870 
also seems to have a preference for A-type RBCs to form aggregates. STEVORs are also involved in 871 
rosette formation and interact with glycophorin C (CD236R) [299]. This latter interaction is proposed to 872 
promote invasion by protecting against invasion-inhibiting Abs. Pentameric IgM appears to strengthen the 873 
binding between iRBCs and uninfected RBCs in rosettes and is able to bind nonspecifically with its Fc 874 
region to two molecules of the PfEMP-1 HB3VAR06 variant [300]. This binding, however, does not 875 
protect the iRBC from opsonized phagocytosis. Nonspecific binding of IgM is also reported with another 876 
PfEMP-1 variant, VAR2CSA, which mediates binding to the syncytiotrophoblast surface through CSA. 877 
This interaction does block the recognition of the iRBC by protective IgGs without affecting cytoadhesion 878 
to CSA [301]. Also other serum components such as complement factor H, albumin and self-Abs against 879 
band 3 possess rosette-promoting properties [75]. Rosetting is also reported with other parasite species, 880 
including the human parasite P. vivax [281, 282, 299] and the rodent parasite P. chabaudi [302]. Rosette 881 
formation with P. vivax is more common than with P. falciparum, and is mediated by glycophorin C, but 882 
not by glycophorin A or CR1 [299]. The hypothesis that rosetting through glycophorin C binding 883 
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facilitates merozoite invasion seems very unlikely for P. vivax, since mature erythrocytes rather than 884 
reticulocytes form rosettes and P. vivax almost exclusively infect reticulocytes.  885 
3.3.1.3. Platelet-mediated autoagglutination 886 
Due to their high adhesive phenotype, iRBCs  also interact with each other to form autoagglutinates or 887 
clumps, a process mediated by platelets (reviewed in [8]). Platelets act as bridging cells between two 888 
iRBCs and autoagglutination only occurs with those P. falciparum lines that are able to bind to platelet-889 
CD36, whereas contradictory data exist for globular C1q receptor (gC1qR/HABP1/p32) and P-selectin 890 
(CD62P) [303-306]. Platelet-mediated autoagglutination is associated with CM, since 100% of P. 891 
falciparum isolates from Thai patients with CM induced clumping compared to 40-41% of isolates from 892 
uncomplicated or severe non-CM patients [307]. Furthermore, autoagglutinates formed by CM isolates 893 
were much bigger than those formed by isolates from patients without CM, suggesting that they may 894 
cause microcirculatory obstruction and impair blood flow in the brain. Platelets may also act as bridges 895 
between iRBCs and ECs and, as such, mediate endothelial cytoadhesion in the microvasculature of organs 896 
devoid of specific receptors such as the brain that normally does not express CD36 [308]. 897 
Autoagglutination has also been found in blood samples of P. vivax patients, but the mechanism of this 898 
has not been described yet [309].  899 
3.3.2. Antigen variation and antigen diversity 900 
Protective Abs are generated by the immune system and interfere with invasion and cytoadherence as 901 
described in section 2.1.3. In order to establish a prolonged chronic infection that allows continuous 902 
parasite transmission, many pathogens, including Plasmodium species, evade the immune response by 903 
altering the expression of surface proteins, a process called phenotypic or antigenic variation (reviewed in 904 
[31, 310]). Furthermore, antigenic diversity, i.e. small clonal variations in the sequence of exposed 905 
proteins, enables the parasites to evade immune mechanisms elicited to the same antigen during previous 906 
exposures. Both mechanisms contribute to the failure of the host to generate protective immunity, and are 907 
a major bottleneck for the generation of an effective vaccine [311].  908 
The mechanisms of antigenic variation are best characterized for the var multigene family encoding 909 
PfEMP-1, the main parasite ligand involved in cytoadherence. On average 60 var genes are distributed in 910 
clusters across the different chromosomes. They are divided into three main subgroups, group A, B and C 911 
var genes and two intermediate groups B/A and B/C, in addition to the more conserved genes var1, 912 
var2csa and var3. These subgroups differ in their genomic localization, i.e. subtelomeric or close to the 913 
centromeres, and in their extracellular domain structure [312, 313]. Furthermore, a set of conserved 914 
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tandem domain cassettes have been identified [314]. Some of these are found in all P. falciparum 915 
genomes and code for a domain structure that spans the entire length of the PfEMP-1 protein, such as 916 
var1 (domain cassette 1), var2csa (domain cassette 2), and var3 (domain cassette 3), whereas the 917 
remaining domain cassettes encode two to four domains. The association between specific domain 918 
cassettes and severe malaria is discussed later in section 4.1.1.  919 
Expression of the var gene family is subject to allelic exclusion, meaning that one parasite expresses only 920 
one variant at a time, and switching to another variant occurs to evade specific Ab-responses [31]. Unlike 921 
African trypanosomes which comprise more than thousand variant surface glycoprotein (vsg) genes, the 922 
P. falciparum genome contains only ~60 members of the var gene multifamily (even though the overall 923 
var gene repertoire is thought to be extremely large due to the extensive diversity of this multigene family 924 
between strains and isolates). How the parasite prevents rapid exhaustion of the repertoire during chronic 925 
infection is not known, but different scenarios are proposed [31]. For instance, parasites may adjust the 926 
antigen switching rate to the time necessary for the host to mount a protective immune response or they 927 
may use a kind of sensing machinery, which would change switching rates depending on the presence of 928 
Abs at the surface of the iRBCs. Which variant is expressed at the surface of the iRBC is tightly regulated 929 
to ensure that only a single var gene is expressed at a time while the rest of the family is maintained 930 
transcriptionally silent. The mechanisms regulating this on-off switching have not yet been elucidated 931 
completely, but it is known that it is a highly organized process that mainly relies on epigenetic processes 932 
including post-translational histone modifications and differential sub-nuclear localization [31, 315, 316]. 933 
Recently, it was found that antisense long noncoding RNAs (lncRNAs) initiating from var introns are 934 
incorporated into chromatin, and that expression of these antisense lncRNAs in trans triggers activation 935 
of a silent var gene [317]. Also the expression of specific var gene subgroups is tightly regulated, as 936 
PfRNase II, a chromatin-associated exoribonuclease, mediates the degradation of nascent RNA and 937 
controls the silencing of group A var genes implicated in the pathogenesis of CM [318]. Furthermore, the 938 
overall organization of var genes is conserved among genetically different parasites, but their repertoires 939 
vary.  940 
It is interesting to note that a high rate of recombinations in the first exon of the var genes has been 941 
detected during mitosis of the erythrocytic stage of the parasite [319]. These recombinations preserve the 942 
domain structure of the PfEMP-1 protein and may result in the formation of large numbers of new 943 
antigenic structures within a single patient, suggesting that the var gene sequence polymorphisms arise 944 
during the asexual parts of the life cycle of the parasite.  945 
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Also other surface-exposed epitopes on iRBCs, e.g. RIFINs and STEVORS and other members of the 946 
PIR multigene family, in the different Plasmodium species are subject to antigenic variation. For 947 
example, multiple RIFIN and STEVOR variants may be expressed simultaneously onto the iRBC surface 948 
[31, 320, 321], and antigenic variation of RIFIN and STEVOR proteins on the merozoite surface may 949 
contribute to immune evasion by camouflaging conserved merozoite surface antigens involved in the 950 
invasion process [31]. Furthermore, vector transmission of P. chabaudi attenuates parasite virulence 951 
through modulation of the cir gene expression and by inducing an enhanced immune response [322]. 952 
Whether both phenomena are interrelated is currently unknown.  953 
Antigenic diversity is important in the multigene families and also in other genes encoding for 954 
immunologically exposed proteins, in particular proteins on the surface of merozoites and proteins 955 
involved in erythrocyte invasion. This diversity is maintained in parasite populations by balancing 956 
evolution (see section 1.1) and also contributes to immune evasion. This became particularly clear in the 957 
trials with vaccine candidates such as MSP proteins and AMA-1, which were able to generate efficient 958 
immune responses against parasites carrying the same allele of the antigen, but the field efficacy remained 959 
low because of the low cross-reaction to diverse allelic variants present in the population [323, 324]. 960 
 961 
4. Imbalances result in severe pathology 962 
A perfectly tuned balance between antiparasite immunity and immune evasion by the parasite is crucial to 963 
avoid pathology (Figure 2A). Most infected individuals manage to fulfill this demanding task, often 964 
supported by antimalarial treatment. However, in approximately 1% of the infected patients, mostly 965 
nonimmune residents, travelers and primigravidae, this balance is disrupted and severe disease ensues. 966 
Severe complications are most common with P. falciparum, but also with P. vivax and P. knowlesi, severe 967 
disease with a possible lethal outcome is increasingly reported [325-327].  968 
Therefore, we will discuss how imbalances can exacerbate the development of pathologies and may be 969 
life-threatening or even lethal. Extensive blood vessel obstruction might occur when the generated 970 
immune response is insufficient to limit parasite replication (section 4.1). Thereby, a highly activated 971 
endothelium supports widespread cytoadhesion of mature-stage iRBCs in the microvasculature of several 972 
organs. Conversely, an exaggerated inflammation may occur, with equally devastating consequences 973 
(section 4.2). Both situations are compared in Figure 5, and may occur separately or simultaneously in 974 
specific organs in either patients or mouse models, leading to distinct complications which are classified 975 
according to the immunological imbalances in Figure 2 and section 6.  976 
 977 
4.1. Blood flow obstruction causes hypoxia  978 
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Parasite sequestration may cause metabolic disturbances by compromising the blood circulation and thus 979 
by inducing hypoxia and lactic acidosis. This may occur in several tissues and organs, including the brain, 980 
the lungs and the placenta, and can further be aggravated by local inflammation and immunopathological 981 
reactions that damage vascular integrity (Figure 5A). These imbalances are central in a variety of 982 
complications, including CM, placenta-associated malaria (PAM), MA-ARDS and acidosis [328]. 983 
 984 
4.1.1. Excessive iRBC sequestration 985 
In P. falciparum-infections, the extent of iRBC sequestration varies between individual microvessels, 986 
between tissues and according to the severity of the infection [329]. Although it also occurs in patients 987 
with uncomplicated or asymptomatic infections, high organ-specific parasite loads are associated with 988 
severe disease as demonstrated in brains and lungs of patients who died from CM or MA-ARDS and in 989 
placentas from women with P. falciparum-associated PAM [233, 329-333]. Furthermore, in CM high 990 
parasite loads are also found in several other organs besides the brain, including lungs, intestine, kidneys 991 
and skin, indicating that CM is characterized by a high total parasite biomass [334-336]. The parasite load 992 
in P. vivax-infections is much lower than with P. falciparum, but with both parasites total parasite 993 
biomass is associated with severe disease [274].  994 
Antigenic variation promotes effective sequestration and thus contributes to pathology. In people infected 995 
with P. falciparum, some var members are dominantly expressed or confer a growth advantage within 996 
specific tissues and are associated with severe complications. As an example, positive selection of 997 
infected red cells expressing VAR2CSA (domain cassette 2) occurs in primigravid women due to the 998 
presence of the placenta where they can bind to CSA [337, 338]. Sequestration of iRBCs (and 999 
subsequently phagocytes) at the maternal side of the placenta reduces the blood flow through the 1000 
intervillous area and results in thickening of the trophoblastic basement membrane and impaired transport 1001 
of maternal nutrients and oxygen across the placenta to the fetus [339]. Interference with this binding by 1002 
specific Abs prevents PAM, highlighting the importance of site-specific sequestration in malaria 1003 
pathology. For other complications, the association between particular var gene expression and pathology 1004 
is less clear. A clinicopathological study performed on fatal pediatric patients in Malawi suggested that 1005 
distinct var genes are dominantly expressed in the different organs of the same patients, although further 1006 
conclusions are difficult in view of the technical limitations [340]. Var genes containing domain cassettes 1007 
8 or 13 are preferentially upregulated in iRBCs that bind to primary microvascular ECs from brain, lungs 1008 
and skin, are associated with severe malaria and are recognized by Abs from young African children from 1009 
malaria-endemic regions [108, 341-343]. Interestingly, PfEMP1 variants containing domain cassettes 8 or 1010 
13 bind to EPCR, which is important in the regulation of inflammation and coagulation, and whose 1011 
expression is decreased in the brain of CM patients [344, 345]. These data indicate that severe falciparum 1012 
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malaria is associated with a small subset of var genes that promote a particular type of microvascular 1013 
sequestration, conferring a growth advantage in malaria-naïve individuals. Besides cytoadherence to the 1014 
endothelium, rosetting and autoagglutination, if present, also contribute to microvascular obstruction and 1015 
were found to be associated with severe disease in African children [295, 296, 346].  1016 
Differences in the cytoadherence pattern exist between human and rodent parasite species and strains, 1017 
which may in part be due to the species-specific nature of these adhesin-receptor interactions. In both P. 1018 
falciparum-infected patients and mice with severe malaria infections, heterogeneous obstruction of 1019 
microcirculatory blood flow was recorded, and the degree of obstruction was proportional to the extent of 1020 
ischemia and to the disease severity [347-354]. In P. falciparum-infected patients with CM, massive 1021 
iRBC cytoadherence is observed in the brain microvasculature [329, 335]. The intravascular presence of 1022 
leukocytes in the brain has long been debated, however, an increasing number of recent papers clearly 1023 
show the presence of monocytes and platelets on brain autopsies from fatal CM patients alongside with 1024 
iRBCs [355, 356]. In mice with experimental CM, brain microvascular obstruction is mainly mediated by 1025 
cytoadherent CD8+ T cells and ICAM1+ monocytes/macrophages in the presence of accumulating iRBCs 1026 
[357-361]. Interestingly, P. berghei ANKA parasites were found to be slowed down in the cerebral 1027 
microcirculation, but they never became completely arrested [362]. Regardless of differences in the cell 1028 
type causing the obstruction, obstruction with associated hypoxia is present, as witnessed by the 1029 
heterogeneous pattern of neuronal and perivascular hypoxia that is found scattered throughout the brain 1030 
and that is significantly higher in brains of mice with CM compared to non-CM brains [363].  1031 
Both iRBCs and inflammatory cells are present in the pulmonary microvasculature of mice and patients 1032 
with MA-ARDS or CM [277, 287, 289, 364-366]. Also in placentas of mice and P. falciparum-infected 1033 
patients, high numbers of iRBCs and leukocytes accumulate in the intervillous maternal space and adhere 1034 
to CSA at the syncytiotrophoblast surface rather than directly to the microvascular endothelial lining 1035 
[367-370]. The expression of variants binding CSA creates a favorable niche for optimal parasite 1036 
replication since monocytes/macrophages are not well equipped to phagocytose CSA-binding iRBCs as 1037 
these do not bind to CD36 (see section 2.1.1) [371]. This may lead to high parasite burdens in the 1038 
placenta, and parasites may be undetectable in the peripheral circulation while high parasite loads (>30% 1039 
iRBCs) are locally found in the placenta [333].  1040 
Severe disease affecting brain, lungs and placenta is increasingly reported with P. vivax [325-327]. It is 1041 
currently unclear whether local P. vivax sequestration occurs and significantly contributes to these types 1042 
of severe pathologies [277, 372]. Sequestration is suggested to occur in spleen and bone marrow, where it 1043 
contributes to systemic inflammation. Thus, a different underlying disease mechanism seems to be 1044 
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operating in severe P. vivax disease, in which systemic and local inflammation rather than local 1045 
microvascular obstruction due to iRBC sequestration seem to play a dominant role [274].  1046 
Hypoxia-inducible factor-1α (HIF-1α), a transcription factor specifically upregulated by hypoxia, is 1047 
similarly induced in brain ECs of mice with and without CM. Activation of HIF-1 triggers the 1048 
transcription of several genes implicated in protection against ischemia, i.e. genes encoding proteins 1049 
involved in glycolysis, blood flow and oxygen delivery to tissues including vascular endothelial growth 1050 
factor (VEGF) and erythropoietin (Epo) [373]. For example, in the brain, Epo protects neural tissues 1051 
against oxidative damage, among others by stimulating neural stem cell proliferation and differentiation 1052 
and neuron survival [374]. Whereas HIF-1α could not be detected in postmortem brains of severe malaria 1053 
patients, HIF-2α, VEGF and Epo staining was detected at similar levels in different areas of CM and non-1054 
CM brains [375, 376]. Epo receptor (EpoR) staining is significantly higher in CM brains than in non-CM 1055 
brains, and the frequency of vascular HIF-2α and EpoR staining is positively correlated with iRBC 1056 
sequestration, indicating that they are principally upregulated in local hypoxic areas [375, 376]. In mice 1057 
with CM, administration of exogenous Epo decreased cerebral hypoxia, HIF-1α, VEGF and activities of 1058 
calpain and caspase and improved survival [377]. Whether exogenous Epo is also beneficial as adjunctive 1059 
treatment for human CM is currently under investigation. Even though high plasma Epo levels are 1060 
associated with protection against neurological sequelae in Kenyan children, warranty is needed since 1061 
high plasma Epo in Ugandan children is associated with prolonged coma duration and increased mortality 1062 
[378, 379]. In general, these data indicate that local hypoxic areas exist in the brain that are associated 1063 
with sequestration, but that hypoxia itself is not sufficient to explain cerebral pathology.  1064 
Hypoxia may also be induced in malaria-infected placentas, since hif-1α, cox-1 and cox-2, but not vegf 1065 
mRNA expression are observed in placentas from Colombian patients with submicroscopical infections 1066 
[380]. 1067 
Hypoxia induced by local decreases in blood flow is further aggravated by impaired oxygen delivery, e.g. 1068 
caused by anemia or hypovolemia [381]. Increased oxidative stress induced by blood parasites may 1069 
oxidize Hb into metHb, which is unable to bind oxygen. Increased metHb and carboxyHb levels have 1070 
been documented in uncomplicated and severe malaria infections [382, 383] and in mice with 1071 
experimental CM [219], and may contribute to impaired oxygen carriage and delivery. Furthermore, 1072 
oxygen consumption in tissues, as measured in skeletal muscles from patients with uncomplicated and 1073 
severe malaria, is increased and further contributes to the imbalance between oxygen delivery versus 1074 
oxygen demand [384, 385]. 1075 
 1076 
4.1.2. Metabolic changes 1077 
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Hypoxia results in increased lactate concentrations as is observed in venous blood and cerebrospinal fluid 1078 
(CSF) from mice and patients with severe complications, and hyperlactatemia is strongly associated with 1079 
a fatal outcome [350, 386-390]. Lactate, together with other unidentified anions, lowers the pH of the 1080 
blood and acidemia develops when the natural buffering capacity of the blood is exceeded, further 1081 
complicating severe disease [391]. Respiratory distress in African children with severe malarial anemia 1082 
(SMA) often reflects lactic acidosis due to hypoxia, since blood transfusion (i.e. increasing oxygen 1083 
supply) decreased blood lactate levels and improved respiratory abnormalities [392]. Lactate could 1084 
possibly also have a damaging effect on brain endothelium during CM [393]. Hyperlactatemia may have 1085 
different origins, including production by the parasite itself and by uncontrolled muscle contraction 1086 
during seizures [387, 394]. Nonetheless, the most important contributor is anaerobic respiration in poorly 1087 
perfused tissues as suggested by increased lactate:pyruvate ratios in patients with complicated malaria 1088 
[395], the association of lactate levels with poor microvascular function (defined as the capacity to 1089 
increase oxygen delivery in response to ischemia), both in severe P. falciparum and severe P. vivax 1090 
infections [274, 385], and the association between lactate and total parasite biomass and blood vessel 1091 
obstruction [353]. Increased blood lactate levels can also be explained by decreased lactate clearance. 1092 
However, the fact that hepatic gluconeogenesis, which is the major route for lactate clearance, is not 1093 
impaired argues against this hypothesis [387, 396]. Furthermore, lactate acidosis does not appear to 1094 
originate from hypovolemia and should therefore not be treated with liberal fluid resuscitation, as this 1095 
may result in pulmonary edema [397].  1096 
Bicarbonate is the major extracellular buffering system in the body, because it can be adjusted very 1097 
effectively by lungs and kidneys. Thus, when blood pH decreases, the body will respond by expelling 1098 
more carbon dioxide (CO2) by increasing the breathing rate or depth. Deep breathing is frequently 1099 
observed in patients with complicated malaria and is often a sign of severe metabolic acidosis, a 1100 
complication which is independently associated with mortality according to one of the largest randomized 1101 
control trials with more than 5000 African children with severe falciparum malaria [398]. Furthermore, 1102 
bicarbonate levels are decreased in severe malaria compared to uncomplicated malaria [399], and in 1103 
patients who died from CM or survived with complications compared to patients who made a full 1104 
recovery [400]. 1105 
Hypo- and hyperglycemia (reviewed in [401]) and other metabolic disturbances also occur in malaria, but 1106 
are out of the scope of this review. 1107 
 1108 
4.1.3. Altered vasomotor activity  1109 
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To optimize oxygen delivery and to limit tissue toxicity in hypoxic areas, local or systemic compensation 1110 
mechanisms are activated. Most tissues respond to hypoxia by vasodilation. However, if this occurs in the 1111 
brain, intracranial pressure increases resulting in brain swelling and decreased cerebral perfusion pressure. 1112 
Brain compression together with decreased perfusion may further aggravate the already existing hypoxia 1113 
as observed in unconscious children and adults with CM [402-404]. Furthermore, when intracranial 1114 
pressure is severely increased, brain stem compression and cardiorespiratory arrest may ensue which 1115 
often results in death or neurologic sequelae upon survival. Besides vasodilatation, edema is another 1116 
mechanism leading to increased intracranial pressure and is discussed in section 4.2.4. Since brain 1117 
swelling appears to be a crucial determinant for the outcome of cerebral malaria, it may also imply that 1118 
ventilatory support, to maintain the patient breathing till the exaggerated intracranial pressure resolves, 1119 
might be life-saving [405].   1120 
Based on the literature, it is hard to conclude if compensatory vasodilation occurs or not. Increased blood 1121 
flows have been observed in microvessels adjacent to clogged ones in brains of CM patients and in larger 1122 
vessels in rectal mucosa of severe malaria patients [348, 406]. In mice with hyperparasitemia and anemia, 1123 
cerebral blood flow was increased and minor brain swelling was observed [407]. Furthermore, several 1124 
mediators are produced during infection that can regulate the vascular tone by influencing vascular 1125 
smooth muscle cell contraction. Endothelin-1 (ET-1) is a potent vasoconstrictor and is produced by 1126 
injured or ischemic ECs and in response to TNF. Bioactive ET-1 levels and its precursor big-ET-1 are 1127 
increased in malaria patients [408, 409], and ET-1 is significantly induced at the transcriptional level in 1128 
brains of mice with CM [410]. A novel inhibitor of ET-1 provided some protection against cerebral 1129 
malaria in mice when administered as adjunctive therapy in combination with artemether, corroborating 1130 
the pathogenic role of ET-1 [411]. In vitro studies indicate that even though endothelial ET-1 secretion is 1131 
increased during hypoxic situations, iRBCs are able to scavenge ET-1 and thereby inhibit ET-1 functions 1132 
[412]. Since substantial iRBC sequestration occurs in the microvasculature, this may be a strategy by 1133 
which the parasite prevents vasoconstriction. Also angiotensin II (AT-II) promotes vasoconstriction, 1134 
however, genetic polymorphisms in angiotensin I converting enzyme (ACE-I) or ACE-II, which result in 1135 
increased levels of AT-II, are associated with protection against CM [413]. The latter finding may be 1136 
related to the antiplasmodial activity of AT-II [414]. Interestingly, inhibition of either ACE or the AT1-1137 
receptor with captopril or losartan protects against murine CM by decreasing splenic T cell activation 1138 
[415]. 1139 
NO is one of the main vasodilators and decreased NO bioavailability may be an important mechanism by 1140 
which compensatory vasodilation is impaired. Low NO bioavailability is observed in a large proportion of 1141 
patients with severe complications and in mice with CM and may have different etiologies [219, 384, 416, 1142 
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417]. Due to intravascular hemolysis, large amounts of free Hb and arginase are released in the 1143 
circulation. Free Hb may scavenge NO produced by ECs resulting in MetHb and nitrate formation, 1144 
whereas arginase will convert L-arginine into L-ornithine. In this way, less L-arginine is available for 1145 
NOS-mediated production of NO. Furthermore, when L-arginine concentrations are low, NOS will 1146 
preferentially synthesize superoxide radicals (O2-) which may interact with NO to form the highly reactive 1147 
peroxynitrite (ONOO-). The decrease in tetrahydrobiopterin, an important cofactor for NOS-mediated NO 1148 
production, and the concomitant increase in dihydrobiopterin further favors the peroxynitrite formation 1149 
and oxidative stress at the expense of NO production [418]. Indoleamine-2,3-dioxygenase (Ido)-derived 1150 
kynurenine is produced by the inflamed endothelium and contributes to arterial vessel relaxation and 1151 
hypotension in P. berghei-infected mice with and without CM [419]. Furthermore, plasma levels of C-1152 
type natriuretic peptide (CNP), another vasorelaxant mediator, are slightly decreased in severe malaria 1153 
patients [408].  1154 
In general, the local vasomotor tone will depend on the overall balance between mediators inducing 1155 
vasoconstriction or vasodilation. Accordingly, the vascular tone may be differentially regulated in large 1156 
and small vessels and between different vascular beds. Consequently, measuring systemic levels of these 1157 
mediators may not be informative to predict the local microvascular tone. Thus, even though kynurenine 1158 
is induced by the vascular endothelium, vasoconstrictors probably predominate during CM in mice, since 1159 
hypoargininemia, increased MetHb levels and microcirculatory collapse are observed and 1160 
pharmacological vascular smooth muscle cell relaxation by exogenous NO, CO, iloprost (a synthetic 1161 
prostacyclin analog) or nimodipine (a calcium channel blocker) improved survival chances from CM 1162 
[213, 219, 350, 351, 420, 421]. Inhaled NO also resulted in decreased systemic inflammation and 1163 
endothelial activation in murine CM [422]. Interestingly, exogenous NO-administration also protects 1164 
against murine CM through an unrelated mechanism. It activates the transcription factor nuclear factor 1165 
erythroid 2-related factor 2 (Nrf-2), which is a sensor of oxidative stress [423]. Nrf-2 subsequently 1166 
induces HO-1, which produces CO that protects by binding to cell-free Hb, blocking its oxidation to toxic 1167 
and inflammatory MetHb and other derivatives. This protective mechanism of NO is also related to the 1168 
decreased activation of pathogenic T cells. Furthermore, phenoxybenzamine, an alpha-blocker and 1169 
vasodilator, and exogenous CO prevented pulmonary edema in P. berghei-infected mice [424, 425]. 1170 
Together these data indicate that cerebral and pulmonary complications in mice are most likely associated 1171 
with impaired vasodilation. In human malaria patients, however, the occurrence of vasodilation may be a 1172 
more heterogeneous phenomenon with variations in patients, organs and vessels.  1173 
 1174 
4.2. Disproportional activation of proinflammatory immune mechanisms 1175 
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A strong and robust immune response is required to combat the infection. However, the activated cells 1176 
and the produced mediators will also interact with the surrounding vessel walls thereby promoting a 1177 
procoagulant state and increased permeability. When inflammation and endothelial dysfunction exceed a 1178 
treshold, edema and/or hemorrhages may occur leading to parenchymal tissue damage and ultimately 1179 
organ dysfunction, as is observed in several malarial complications, including MA-ARDS. 1180 
 1181 
4.2.1. Excessive endothelial activation  1182 
Systemic microvascular endothelial activation occurs due to the combined effects of sequestration, 1183 
inflammation and the locally released iRBC content during schizont rupture, including heme, Hz, histones 1184 
and GPIs (see section 3.2) [240, 250, 426-430]. This results in exocytosis of Weibel-Palade bodies 1185 
(WPBs), secretion of inflammatory mediators, such as cytokines, chemokines and proteases, tissue factor 1186 
(TF) expression and in upregulation of adhesion molecules. Thus, by measuring plasma levels of 1187 
mediators that are normally stored inside WPBs, e.g. angiopoietin-2 (ANG2) and von Willebrand factor 1188 
(vWF), or soluble adhesion molecules like sP-selectin and sICAM-1, the extent of EC activation can be 1189 
determined.  1190 
EC activation is observed in asymptomatic and symptomatic malaria infections and in infections of other 1191 
etiologies [431, 432]. In human volunteers experimentally infected with P. falciparum, vWF levels 1192 
increase immediately after the onset of blood-stage infection, indicating that endothelial activation is one 1193 
of the first alterations induced by infection [433]. Furthermore, higher levels of endothelial activation 1194 
markers, including ANG2, sICAM-1, and sE-selectin are found with P. vivax compared with P. 1195 
falciparum, despite of significantly lower parasite counts, indicating that P. vivax is a more potent 1196 
activator of the endothelium [434].  1197 
The extent of EC activation is much higher during pathology. ANG2, ANG2/ANG1 and vWF levels 1198 
increase with disease severity and are associated with parasite biomass, lactate levels and mortality rates 1199 
[432, 435-439]. Postmortem analyses of CM brains show high ANG1, ANG2 and Tie2 neuronal and 1200 
endothelial staining [439]. Neuronal ANG1 and ANG2 staining are associated with microhemorrhages, 1201 
whereas no association is found with parasite sequestration. ICAM-1 is also increased in the cerebral 1202 
endothelium of CM patients [440-442], and may augment parasite sequestration [443]. Also in P. vivax 1203 
infections markers of endothelial activation are increased and correlate with severity and with peripheral 1204 
parasitemia [444-446]. No correlation is found with parasite biomass, indicating that circulating iRBCs 1205 
rather than the hidden component activate the endothelium.  1206 
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The ANG-Tie2 axis is able to rapidly modify the endothelial response to possible pathogenic insults such 1207 
as infection and inflammation [447]. ANG1 is constitutively produced and promotes endothelial 1208 
quiescence by signaling through the Tie2 receptor, whereas ANG2 promotes vascular permeability and 1209 
endothelial activation by blocking this receptor. NO regulates this axis by inhibiting the release of ANG2 1210 
from WPBs and by inducing ANG1 [448]. As already mentioned, in a large proportion of patients with 1211 
severe complications and in mice with CM, NO bioavailability is decreased (see section 4.1.3). Thus, due 1212 
to the combined effects of sequestration, inflammation and dysregulation of endothelial activation, pro-1213 
inflammatory signaling cascades are activated, which may lead to endothelial secretion of pro-1214 
inflammatory mediators, alteration of vasomotor activity, cytoskeletal rearrangements resulting in 1215 
permeability changes, induction of a procoagulant state and/or induction of EC apoptosis [433, 449-451].  1216 
4.2.2. Coagulation changes 1217 
Coagulopathy is common in severe malaria and results from a combination of several factors, including 1218 
thrombocytopenia and activation of the coagulation pathway [452]. It is indicative of a poor prognosis 1219 
and may manifest itself as diffuse intravascular coagulation (DIC), ring-form hemorrhages in the brain 1220 
during CM (thereby defining the CM2 subgroup of patients), microhemorrhages in lungs or other forms 1221 
of bleedings [452, 453]. A generalized procoagulant state results in consumption and exhaustion of 1222 
platelets and coagulation factors, which, combined with endothelial damage, results in an increased 1223 
sensitivity to hemorrhages. 1224 
Thrombocytopenia is induced rapidly after the onset of a blood-stage infection [433] and is frequently 1225 
observed in P. falciparum and P. vivax patients [305, 454-459] and in mouse models of malaria [460-1226 
462]. A strong correlation is found between thrombocytopenia and levels of both vWF and activated vWF 1227 
[433]. Endothelial vWF is stored as ultra-large (UL)-vWF multimers or as vWF propeptide in WPB. 1228 
When released during EC activation, these UL-vWF multimers unravel under flow and form platelet-1229 
decorated strings which may bind large numbers of iRBCs [451]. In normal situations, these 1230 
prothrombogenic multimers are rapidly cleaved by the protease a disintegrin and metalloproteinase with a 1231 
thrombospondin type I motif member 13 (ADAMTS13). However, P. falciparum and P. vivax patients 1232 
with severe malaria infections have significantly reduced ADAMTS13-activity [274, 399, 454, 463]. 1233 
Thus, the combination of endothelial activation with increased circulating amounts of active and UL-1234 
vWF, together with reduced vWF inactivation by ADAMTS13, may result in intravascular platelet 1235 
aggregation, as observed in brains and lungs of severely ill patients and mice [308, 356, 461, 464-466] 1236 
and in P. falciparum-infected placentas [308]. In P. vivax patients, platelet numbers are also positively 1237 
correlated with ANG1 and negatively with ANG2 and the ANG2/ANG1 ratio [444].  1238 
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Furthermore, the urokinase plasminogen activating receptor (uPAR) may participate in endothelial 1239 
platelet adhesion [467]. Platelet depletion or inhibition of platelet adhesion to the endothelium, e.g. by 1240 
uPAR deficiency or treatment with aprotinin (a nonspecific inhibitor of plasmin that also interferes with 1241 
platelet adhesion to the endothelium), significantly decreases mortality from pulmonary and cerebral 1242 
pathology and ameliorates thrombocytopenia in mice, underlining the pathological role of platelet 1243 
sequestration in brain and lungs [461, 464, 468-470].  1244 
Platelet adhesion to ECs provides additional receptors to microvascular beds that otherwise lack 1245 
important adhesion receptors, e.g. CD36 in the brain, and may, therefore, enhance iRBC sequestration to 1246 
the activated endothelium [308]. Increased iRBC sequestration together with platelet-mediated clumping 1247 
augments immune evasion and favors parasite replication, which may contribute to higher parasite loads 1248 
and aggravate blood-flow obstruction and microvascular disease. Furthermore, platelet adhesion 1249 
potentiates the cytotoxic effects of iRBCs on the activated endothelium, including EC apoptosis. They 1250 
further increase permeability and reduce transendothelial electrical resistance (TEER) [449] and they 1251 
promote inflammation by secretion of inflammatory or proapoptotic molecules upon activation, e.g. 1252 
transforming growth factor-1 (TGF-1) and PF4/CXCL4 [470, 471]. TGF-1 induces EC apoptosis and 1253 
PF4/CXCL4 contributes to leukocyte recruitment, T cell activation and cytokine production by 1254 
monocytes. Thus, even though platelets are implicated in antimalarial immunity, they also significantly 1255 
contribute to severe malarial disease. 1256 
In addition to platelet trapping, increased platelet turnover and active platelet removal may also contribute 1257 
to low platelet numbers in human malaria [145, 457]. Both IgG-mediated platelet phagocytosis and RNIs 1258 
are negatively correlated with platelet counts. Decreased levels of circulating platelets are also associated 1259 
with an increase in the number of MPs, both in mice and in patients, and inhibition of caspase-mediated 1260 
apoptosis of platelets decreases the number of MPs and increases platelet numbers [462, 472]. Bone 1261 
marrow megakaryopoiesis and thrombopoietin production to replenish peripheral platelet numbers seems 1262 
to be normal or slightly increased, indicating that thrombocytopenia originates mainly in the periphery. 1263 
Thus, intravascular platelet adhesion, altered platelet kinetics, active platelet removal and increased 1264 
platelet-derived MP formation may all contribute to thrombocytopenia. Furthermore, thrombocytopenia is 1265 
also associated with peripheral parasitemia levels [305, 455, 458].  1266 
The coagulation cascade is also activated during severe malaria as evidenced by the upregulation of TF in 1267 
human and mouse CM brains [450, 473]. Mature-stage iRBCs induce TF expression on dermal 1268 
microvascular ECs in vitro resulting in the assembly of the TF/factor VIIa (FVIIa) complex, which 1269 
cleaves and activates coagulation factor X. The latter is crucial in the activation of thrombin, which 1270 
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converts fibrinogen into fibrin. Furthermore, MPs promote a procoagulant state, since they may express 1271 
significant amounts of TF, and because they contain large amounts of surface-exposed PS [474]. This 1272 
recruits vitamin K-dependent and gamma-carboxyglutamyl residue-containing coagulation factors (FVII, 1273 
FIX, FX and FII), which significantly enhances the coagulation cascade. 1274 
Levels of anti-thrombin-III (AT-III) are decreased [475, 476] and thrombin-anti-thrombin (TAT) 1275 
complexes are increased [475, 477] in plasma of severe malaria patients, indicating that thrombin 1276 
formation occurs during malaria infection and that coagulation inhibitors are consumed. Plasminogen 1277 
activator inhibitor-1 (PAI-1) levels are increased in malaria patients and levels of fibrin degradation 1278 
products (FDPs) seem to increase with disease severity [478]. Also protein S, protein C and EPCR are 1279 
decreased, resulting in a lower inhibition of the coagulation cascade [345, 478]. Furthermore, in P. vivax-1280 
infected patients thrombocytopenia and coagulation seem to be interrelated, since a negative correlation is 1281 
found between platelet counts, TAT complexes and D-dimers (reviewed in [145]). 1282 
 1283 
4.2.3. Inflammation 1284 
Inflammation is associated with malaria. Whether this inflammation is mild or excessive and contributes 1285 
to pathology depends on the interplay between parasite and host. Insufficient or ineffective immune 1286 
responses result in high parasite load and the release of inflammation-regulating components by the 1287 
parasites (Figure 2A). Excessive inflammation, even at moderate parasitemia, is at the basis of severe 1288 
immunopathological complications in several murine malaria models (Figure 5B). The role of 1289 
inflammation in SMA is discussed in section 4.2.5. Also during MA-ARDS and PAM in both mice and 1290 
patients, abundant leukocyte recruitment and inflammation are evident. Since MA-ARDS often appears 1291 
after therapeutic clearance of parasites, it is supposed to result from excessive inflammation. In CM 1292 
patients iRBC sequestration clearly dominates inflammatory infiltrates. Although signs of inflammation 1293 
are present, it is currently unclear and heavily debated to what extent inflammation contributes to CM 1294 
pathology, among others because anti-inflammatory therapy of CM patients failed to improve survival 1295 
[479]. Little or no iRBC sequestration is present in peripheral organs of severe P. vivax patients and 1296 
inflammatory processes at low parasitemia prevail. In this section, we review the different processes 1297 
which initiate, sustain and aggravate localized inflammatory reactions and associated damage in malaria. 1298 
4.2.3.1. Initiation of inflammation 1299 
It is currently unclear which events initiate inflammation. In static in vitro cocultures, late-stage parasites 1300 
activate inflammatory pathways in ECs, e.g. through activation of NF-kB, resulting in the production of 1301 
cytokines, chemokines and adhesion molecules [427, 480]. Although the need for cytoadherence in this 1302 
42 
 
process has not been formally proven, it is reasonable to assume that parasite sequestration results in local 1303 
endothelial inflammation by the localized release of inflammatory compounds such as free heme, Hz, GPI 1304 
anchors, nucleosomes, and uric acid precipitates and precursors. These immunomodulatory molecules are 1305 
highly inflammatory as previously discussed (see section 3.2) and could be associated with severe 1306 
complications due to excessive inflammation. Also the interaction between parasite adhesins and 1307 
adhesion molecules on ECs may trigger activation of signaling pathways [481].  1308 
4.2.3.2. Activated phagocytic cells 1309 
Both monocyte/macrophage and granulocyte populations expand during malaria infection to augment the 1310 
parasite clearance capacity. High organ-specific parasite loads are associated with severe disease [233, 1311 
274, 329-333], and the proportion of circulating phagocytes containing Hz increases with disease severity 1312 
[482-484]. Phagocytes clean up the iRBC content released during schizont rupture and thus prevent these 1313 
components to cause damage to the vessel wall. Intravascular marginating and/or infiltrating phagocytes 1314 
with or without ingested Hz are observed in brains, lungs and placenta of both mice [367, 485-493] and 1315 
patients [333, 355, 356, 364, 371, 494-500] with CM, malaria-associated acute lung injury (MA-1316 
ALI)/ARDS or PAM, respectively. Furthermore, tissue macrophages e.g. microglia, Kupffer cells and 1317 
alveolar macrophages, are activated during infection in mice and humans [347, 491, 497, 501-503]. 1318 
Widespread microglial activation is not limited to areas of petechial bleedings or iRBC sequestration and 1319 
precedes accumulation of leukocytes and in situ proliferation of CD8+ T cells [491, 503]. Both in human 1320 
and mouse placentas, high numbers of monocytes/macrophages accumulate in the intervillous space, 1321 
especially during chronic infection [332, 333, 367, 371, 495, 500], and high levels of placental chemokine 1322 
expression are associated with monocyte infiltration in human and mouse placentas [367, 504]. Local 1323 
phagocytosis of iRBCs occurs mainly in P. falciparum-infected placentas as evidenced by the presence of 1324 
Hz, parasites and RBCs (both infected and uninfected) in various stages of degradation [332]. 1325 
Nevertheless, phagocytes fail to remove the majority of iRBCs, and this reduced phagocytic capacity may 1326 
partly be related to the inability of VAR2CSA-expressing iRBCs to bind to CD36 (see also sections 2.1.1 1327 
and 4.1.1) [371]. Because of this impaired nonopsonic phagocytic response, more 1328 
monocytes/macrophages are recruited to the placenta and high amounts of toxic mediators, cytokines and 1329 
chemokines are produced. This further augments inflammation and contributes to pathology, with partial 1330 
syncytiotrophoblastic necrosis as a common finding in placentas with high numbers of accumulating 1331 
macrophages [332].  1332 
4.2.3.3. Cytotoxic T cells 1333 
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CD8+ T cells are also observed in the placental intervillous spaces of both infected and non-infected 1334 
women, and CTL numbers are higher in women with chronic P. falciparum-infections, especially in those 1335 
with massive intervillous inflammation [495]. Furthermore, the number of intervillous CTLs are related to 1336 
the percentage of maternal iRBCs and the extent of Hz deposition [495]. Intervillous CTLs from infected 1337 
women are primed to produce IFN- and TNF after in vitro mitogen stimulation [505], indicating that 1338 
proinflammatory immune responses are induced in the placenta. In murine CM, more than 90% of brain 1339 
sequestered CTLs present express the CXC chemokine receptor 3 (CXCR3) [506], which is crucial for the 1340 
cerebral pathogenesis in mice [470, 488, 507, 508]. NK cell-derived IFN- and PF4/CXCL4 stimulate 1341 
expression of CXCR3 on activated T cells in the spleen [470, 506], and IFN- also induces Interferon 1342 
gamma-induced protein 10 (IP-10)/CXCL10 expression in the brain, resulting in recruitment of activated 1343 
T cells to the cerebral vasculature [488, 507, 509]. IP-10/CXCL10 is also associated with human CM, as 1344 
highest IP-10/CXCL10 CSF levels are detected in CM patients, plasma IP-10/CXCL10 levels increase 1345 
with disease severity and increased levels are tightly associated with CM mortality [510, 511]. In mouse 1346 
malaria models both parasite-specific and nonspecific CTLs are generated, although mainly the parasite-1347 
specific CTLs induced by cross-presentation of blood-stage malarial antigens by the CD8+ subset of 1348 
mDCs in the context of MHC class I are pathogenic [512, 513]. Several antigens may be recognized by 1349 
these activated CD8+ T cells, including glideosome-associated protein, and this can occur in murine 1350 
models both with and without CM [514, 515]. The DCs driving the activation of these cells also express 1351 
Clec9A+ [516]. Clec9A is a C-type lectin-like receptor expressed by murine CD8+ mDC and pDCs and 1352 
also by human DCs [517]. This subset of mDCs also expresses BDCA3 and is also augmented in malaria 1353 
patients [518]. Flt3L derived from mast cells is responsible for the expansion of these CD8+ DCs, and 1354 
their depletion abrogates P. berghei ANKA-induced CM in mice [159]. 1355 
In addition to the migration of the activated CD8+ T cells to the brain, a crucial event is the acquisition 1356 
and cross-presentation of malarial antigens by brain ECs. Upon sequestration of P. falciparum-iRBCs 1357 
onto ECs, the ECs appear to acquire malarial antigens, and may become targets for adaptive immunity 1358 
[519]. Also platelets can acquire and cross-present Plasmodium antigens in association with MHC class I 1359 
molecules with the necessary costimulatory signals and contribute to the generation and in situ 1360 
proliferation of parasite-specific CTLs [190, 520]. CD8+ CTLs compromise the BBB by releasing 1361 
perforin and granzyme and by inducing apoptosis through Fas-FasL interaction with subsequent leakage 1362 
of protein-rich fluid across the BBB [358, 521-524]. In CM patients, increased intracranial pressure is a 1363 
major finding and might be due to edema. However, the precise cause of the brain swelling has not yet 1364 
been determined (see following section) and CD8+ T cell accumulation has not been reported. CD8+ T 1365 
cells may have a more prominent pathological role in human MA-ARDS, since both in mice and in 1366 
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humans the alveolar-capillary membrane is damaged with the presence of mononuclear cell infiltrations 1367 
and extensive interstitial and/or alveolar edema formation [364, 365, 425, 489, 490, 499, 525], and 1368 
depletion of CD8+ T cells or IP-10/CXCL10 deficiency in MA-ARDS-susceptible mice prevents 1369 
pulmonary edema [428, 489, 526, 527]. Furthermore, CTLs contribute to spleen remodeling by killing 1370 
metallophilic macrophages in the inner border of the marginal zone [528], which could compromise the 1371 
generation of an optimal splenic immune response (see section 5.5). 1372 
4.2.3.4. Cytokines and other soluble inflammatory mediators 1373 
Due to the presence of these inflammatory cells in peripheral organs, considerable amounts of cytokines 1374 
(e.g. TNF, IL-1, IL-6), ROS and other inflammatory mediators [e.g. gelatinase B/matrix 1375 
metalloproteinase-9 (MMP-9) and VEGF] are produced that further enhance inflammation, participate in 1376 
endothelial remodeling, and contribute to tissue injury. For example, high amounts of ROS produced by 1377 
phagocytic cells can cause oxidative damage. In P. vivax, mainly CD14hiCD16/FcRIIIA+ ‘inflammatory’ 1378 
monocytes produce high amounts of ROS [45]. Antioxidative treatment protects mice from CM [529], 1379 
even though no increased levels of protein carbonylation nor oxidation are found in the brain, and mice 1380 
deficient in NADPH oxidase are as susceptible as WT to develop CM [66]. The antioxidative defense in 1381 
the brain of mice with CM appears to be mediated by HO-1 and glutathione peroxidase, whereas the 1382 
expression of SOD and catalase is decreased [530]. Antioxidative adjunctive therapeutic treatment of 1383 
severely ill P. falciparum patients was not effective [531].  1384 
Also excessive cytokine production may further enhance pathology. Local inflammatory reactions are 1385 
best characterized in the murine CM model. Already early in the infection IFN--producing NK cells are 1386 
among the first cells to be recruited to the brain in murine CM [506]. This increases the expression of 1387 
adhesion molecules and chemokines by the cerebral endothelium and further enhances leukocyte 1388 
recruitment and sequestration [488, 532]. The adhesion molecules P-selectin, ICAM-1, and its ligand 1389 
LFA-1 support leukocyte and platelet adhesion [461, 464, 493, 533-535], and chemokines, including CC-1390 
chemokines [e.g. MCP-1/CCL2 and macrophage inflammatory protein-1α (MIP-1α/CCL3)] and CXC-1391 
chemokines [e.g. PF4/CXCL4, monokine induced by gamma-interferon (MIG/CXCL9), IP-10/CXCL10 1392 
and interferon-inducible T-cell alpha chemoattractant (I-TAC/CXCL11)] recruit more leukocytes to the 1393 
brain, including activated CD4+ and CD8+ T cells [488, 507, 508, 536]. The importance of IFN- in 1394 
murine CM is further illustrated by the fact that depletion or deficiency of IFN- or the IFN- receptor 1395 
(IFN-R) protects mice from CM [488, 537-542] and IFN-R expression is only upregulated in brains of 1396 
mice with CM [543]. Excessive IFN- production is also associated with cerebral pathology in human 1397 
disease, since highest IFN- staining is detected in brains of P. falciparum-patients who died from this 1398 
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neuropathology [544], and both IFN- and IFN-/IL-10 ratios increase with disease severity in P. vivax-1399 
patients [545]. Inflammation, as shown by increased peripheral blood levels of IFN-, IL-2 and TNF, is 1400 
also high during placental malaria in pregnant women submicroscopically infected with P. vivax [380]. 1401 
Most peculiarly, T cell trafficking to the lungs and pulmonary chemokine expression in mice are 1402 
increased in the absence of IFN- signaling [546, 547], indicating that different mechanisms orchestrate 1403 
brain and pulmonary inflammation.  1404 
An important determinant of IFN- expression and immunopathology in mice is the NK complex (NKC) 1405 
[548, 549]. The NKC is a genomic region that is comprised of different genes and multigene families 1406 
encoding receptors that positively or negatively influence the cytotoxic activity and/or cytokine 1407 
production by cells expressing these receptors, i.e. NK cells and NKT cells. The susceptibility of mouse 1408 
strains towards malaria immunopathology is in part determined by the NKC genotype, since introduction 1409 
of the NKC of disease-susceptible mouse strains (e.g. C57BL/6) into disease-resistant strains (e.g. 1410 
BALB/c) increases the susceptibility to severe pathology. Among the cell types expressing these NKC-1411 
encoded receptors, mainly CD1d-restricted NKT cells control systemic proinflammatory cytokine 1412 
production, because in both CD1d-deficient BALB/c mice and BALB/c mice containing the C57BL/6-1413 
NKC, IFN- responses were not timely downregulated and no switch towards IL-4 production was 1414 
observed [548]. Two specific loci in the C57BL/6 are responsible for this effect [550]. Thus, by their 1415 
cytokine secretion, CD1d-restricted NKT cells determine the magnitude of the proinflammatory response 1416 
and, as such, influence the individual outcome in the balance between antiparasite immunity and 1417 
inflammation. 1418 
Also cytokines of the TNF family play important roles in murine CM. Interaction of lymphocyte-derived 1419 
lymphotoxin 3 (LT3)/LT12 with TNF receptor 2 (TNFR2) and LT receptor (LTR) activates the 1420 
endothelium and augments monocyte/macrophage, T cell and platelet adhesion in the brain by increasing 1421 
ICAM-1 expression on microvascular ECs [449, 551, 552]. Moreover, several cytokines synergize to 1422 
augment the expression of adhesion molecules [429]. Furthermore, TNF can alter the local vasomotor 1423 
tone by inducing the release of vasoconstrictors by the endothelium, e.g. ET-1 [408], and can induce MP 1424 
shedding from the endothelium [449]. TNF levels increase with disease severity and are maximal in 1425 
severe malaria patients, both with P. falciparum and P. vivax [446, 477, 545, 553-562]. Highest brain 1426 
levels of TNF are observed in P. falciparum-patients who died from cerebral pathology [442, 544]. 1427 
Despite the pathogenic role of TNF in malaria pathology, deficiency of TNF or TNFR1 has no effect on 1428 
murine CM [538, 539, 551, 563-567]. Furthermore, neutralization of TNF in patients with CM appeared 1429 
effective to suppress fever, but it did not improve survival and rather increased neurological sequelae 1430 
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[568]. This might be due to the neutralization of the protective actions of TNF, since TNF is important for 1431 
antiparasite immunity [569-571], or due to the actions of other cytokines such as IFN- and LT- that 1432 
also contribute to cerebral pathology (see above).  1433 
4.2.3.5. Microparticles 1434 
MP shedding may further augment inflammation. Higher levels of circulating MPs of different origin, 1435 
including from iRBCs (see section 3.2.6), noninfected RBCs, ECs, and platelets, are found in severe P. 1436 
falciparum malaria [258, 572] and murine models of CM [260]. MPs are also produced during acute P. 1437 
vivax infection, but the amounts are lower compared to uncomplicated P. falciparum infections [218, 1438 
472]. Whether increased MP shedding is also associated with severe P. vivax disease remains to be 1439 
investigated. Inflammation contributes to MP production, since TNF induces a higher degree of MP 1440 
shedding from ECs derived from aspirated subcutaneous tissue of patients with CM than from ECs from 1441 
patients with uncomplicated malarial disease [573], and circulating MPs of endothelial origin are highest 1442 
in malaria patients with cerebral pathology [258]. Furthermore, MPs activate diverse immune 1443 
mechanisms in vitro, e.g. iRBC-derived MPs are potent inducers of macrophage activation as discussed in 1444 
section 3.2.6 [257], and platelet-derived MPs bind to iRBCs, are internalized by human brain 1445 
microvascular ECs and transfer platelet antigens such as CD36 to the iRBC and EC surface [574]. 1446 
Interestingly, endothelium-derived MPs may express MHC class II and other molecules important for 1447 
antigen presentation and are able to enhance CD4+ and CD8+ T cell activation [575]. MPs also contribute 1448 
to immunopathology, as adoptive transfer of labelled plasma MPs from mice with CM indicates that MPs 1449 
rapidly interact with ECs and induce neurological and pulmonary insults [576]. Furthermore, inhibition of 1450 
MP formation, e.g. by genetic targeting of the ATP-binding cassette transporter A1 (ABCA1) or by 1451 
treatment with the low-molecular-weight thiol panthetine, protects mice from CM [260, 577]. Despite of 1452 
this, MPs are not invariably harmful, as they may protect the endothelium and prevent blood loss [474, 1453 
578].  1454 
4.2.4. Vascular hyperpermeability 1455 
Malaria infections may compromise the endothelial barrier in specific organs. Extensive non-cardiogenic 1456 
pulmonary edema is well established in both mice and patients with MA-ALI and in its more severe form 1457 
MA-ARDS (reviewed in [453]). VEGF may increase vascular permeability by dissociation of vascular 1458 
endothelial (VE)-cadherin from its cytoskeletal anchoring protein -catenin [579] and by redistribution of 1459 
actin, occludin and zona occludens-1 (ZO-1) [580]. VEGF is positively correlated with edema in lungs of 1460 
mice with MA-ARDS [229], and contributes significantly to fatal edema in mice with MA-ALI [425]. In 1461 
normal situations, pulmonary VEGF is predominantly produced by epithelial cells and diffuses through 1462 
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the alveolar-capillary membrane where it binds to VEGF receptors on the vascular endothelium [581]. 1463 
However, during MA-ARDS VEGF transcription is downregulated probably due to Hz-induced 1464 
inflammation that damages the alveolar epithelium [229]. Thus, VEGF-mediated pathology probably 1465 
arises due to high numbers of VEGF-containing immune cells that are mobilized from the spleen to the 1466 
lungs, rather than from de novo synthesis of VEGF in the lungs [229, 425]. Sequestration of iRBCs 1467 
occurs in the pulmonary microvasculature in mice [287, 582, 583] and in P. falciparum-infected patients 1468 
[334, 499], and it is still questionable with P. vivax [277, 364]. In an isolated perfused lung system, 1469 
sequestering iRBC were shown to produce ROS, which decreases TEER indicating barrier loss [584]. 1470 
Furthermore, parasite components released during schizont rupture, e.g. merozoites, GPIs and food 1471 
vacuoles, can alter junctional morphology and disrupt ZO-1, claudin 5 and VE-cadherin in primary lung 1472 
microvascular ECs resulting in interendothelial gap formation [585]. Hz, another component released by 1473 
rupturing schizonts, induces inflammation in the lungs, and Hz levels and pathology are strongly 1474 
correlated with the expression of several inflammatory mediators and the number of immune cells in the 1475 
lungs, including activated CD8+ T cells [229], which contribute to pathology probably by disrupting 1476 
junctional integrity [489]. Alveolar fluid clearance mechanisms are also impaired and contribute to the 1477 
increase in vascular permeability. TNF, which is induced in the lungs by e.g. Hz, is positively correlated 1478 
with pulmonary pathology [229], and reduces the expression and activity of the amiloride-sensitive 1479 
epithelium sodium channel (ENaC) involved in alveolar fluid clearance [581]. Both ENaC expression and 1480 
activity are decreased in lungs of mice with malaria-associated edema [490]. 1481 
The occurrence of pathological vascular permeability changes in CM is less clear. Massive vasogenic and 1482 
also cytotoxic edema are observed in murine CM brains [350, 428, 563, 586, 587], and strategies to 1483 
prevent vascular hyperpermeability protect mice against CM [588]. The bidirectional water channel 1484 
aquaporin 4 (AQP4) is an important regulator of water movement between fluid compartments (blood and 1485 
CSF) and brain parenchyma, and facilitates water movement into brain astrocytes in cytotoxic edema and 1486 
water movement out of the brain in vasogenic edema [589]. In murine CM, deficiency in AQP4 1487 
aggravates the neuropathology [587]. Inflammation and vasogenic edema in murine malaria are tightly 1488 
linked. The hyperpermeability may be directly caused by endothelial activation (see section 4.2.1). As 1489 
ECs may also acquire malarial antigens (see section 4.2.3), it is also tempting to speculate that CD8+ T 1490 
cell cytotoxic activity towards ECs may be a main cause of endothelial barrier damage. 1491 
Focal loss of ZO-1, occludin and vinculin between ECs constituting the BBB is only observed in human 1492 
CM [590] and in vitro studies showed that only iRBCs from CM patients were able to down-regulate the 1493 
transcription of these junctional proteins [591]. However, diffuse microscopic cerebral edema, including 1494 
enlarged perivascular spaces, AQP4 upregulation and VEGF signaling without significantly increased 1495 
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brain weight are frequently observed in adult severe malaria patients with and without CM, and no 1496 
correlations are found with neuropathology [592]. Furthermore, mannitol adjunctive treatment, which 1497 
decreases intracranial pressure by removing water from the brain parenchyma, does not improve survival 1498 
from CM [404, 593]. With neuroimaging of carefully diagnosed CM patients, increased intracranial 1499 
pressure is one of the most common findings [403, 404, 594-596], and in a recent large magnetic 1500 
resonance imaging (MRI) study, severe brain swelling was found in 84% of lethal CM cases (with 1501 
retinopathy), whereas in nonlethal cases the brain swelling was transient [405]. However, the exact 1502 
etiology is currently unclear and might involve venous congestion and/or vasogenic and cytotoxic edema 1503 
[597]. Differences between Asian adults and African children may also be involved. The availability of 1504 
improved MRI technology in endemic areas will hopefully clarify this issue [598].  1505 
 1506 
4.2.5. Erythrocyte destruction and ineffective erythropoiesis 1507 
Hematocrit levels depend on a homeostatic balance between RBC destruction and de novo synthesis in 1508 
hematopoietic tissues. During malaria, RBC destruction is enhanced and, if compensating erythropoiesis 1509 
is impaired, this leads to anemia (reviewed in [599, 600]). Mild to moderate anemia develops in many P. 1510 
falciparum and P. vivax-infected patients, and in endemic regions malaria is one of the most prevalent 1511 
causes of anemia. A small percentage of all infected individuals, mainly young children and pregnant 1512 
women, are prone to develop life-threatening anemia, the most common severe complication of malaria 1513 
infections [326, 327].  1514 
Several mechanisms may contribute to increased red cell destruction. Parasite replication results in 1515 
hemolysis because mature schizonts rupture when releasing the newly formed merozoites. Nevertheless, 1516 
mainly destruction of uninfected RBCs contributes to anemia, a process that is even more pronounced 1517 
with P. vivax [599]. RBC surface expression of complement regulatory proteins CR1 and CD55 is 1518 
decreased, while C3b deposition is increased in P. falciparum-infected patients with SMA [601, 602]. 1519 
Increased complement deposition could result from oxidative damage with subsequent band 3 receptor 1520 
clustering induced by ROS release from phagocytes and/or by transfer of 4-HNE from iRBCs to 1521 
uninfected RBCs in rosettes [73, 601, 603, 604]. Also direct contact with digestive vacuoles covered with 1522 
C3 and C5 convertases mediates deposition of activated C3b and C5b components onto the red cell 1523 
surface [90]. Furthermore, higher surface deposition of IgG and IgM, directed either against autologous 1524 
RBC surface proteins or against parasite antigens inserted in the noninfected RBC membrane after their 1525 
release from the parasite, e.g. parasitic GPIs, is observed [241, 605]. Both mechanisms shorten the 1526 
lifespan of RBCs by targeting these prematurely for CR1-mediated hemophagocytosis. Apoptosis of 1527 
noninfected RBCs, with subsequent deposition of CRP and phagocytosis mediated by FcRIIA may 1528 
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additionally contribute to the development of anemia with P. falciparum and P. yoelii, although this does 1529 
not seem to occur with P. vivax [85, 606, 607]. Different mechanisms may dominate in murine models, 1530 
since anemia associated with rodent malaria seems to be C3-independent [605]. Activation of the adaptive 1531 
immune system may further exacerbate RBC destruction, as CD4+ T cells may contribute by enhancing 1532 
phagocyte activation [608], and even CD8+ T cell-dependent parasite clearance may trigger the loss of 1533 
uninfected erythrocytes in the spleen through an as yet unknown mechanism [137]. 1534 
Anemia results in oxygen shortage [609]. This is sensed in the kidney by decreased hydroxylation and 1535 
enhanced stability of HIFs, and stimulates Epo production. By promoting the proliferation, differentiation 1536 
and maturation of erythroid progenitors, Epo induces erythropoiesis to increase the oxygen delivery 1537 
capacity. In pediatric malaria patients, circulating Epo levels increase with disease severity, highest levels 1538 
are found in severely anemic patients, and erythropoiesis is impaired (reviewed in [599, 600]). This 1539 
suggests that in children the erythropoietic system might be unresponsive to Epo. In contrast, in a large 1540 
percentage of infected adults, the ability to produce adequate Epo levels is impaired, which implies that 1541 
different mechanisms may be responsible for the inefficient erythropoiesis observed in malaria-infected 1542 
children and adults. In P. chabaudi AS-infected A/J mice, sufficient numbers of EpoR+ early erythroid 1543 
progenitors are present in the spleen, but fail to differentiate and mature properly into Hb-producing 1544 
erythroblasts in response to Epo. Consequently, inappropriately low numbers of reticulocytes are released 1545 
in the circulation [610]. Impaired differentiation of early erythroid progenitors into erythroblasts has also 1546 
been suggested to contribute to anemia in Gambian children [611]. The exact mechanisms driving this 1547 
decreased sensitivity towards Epo are not yet fully elucidated, but the release of cytokines (e.g. TNF) and 1548 
Hz may be involved. Increased levels of Hz-containing monocytes are associated with anemia and 1549 
reticulocyte suppression, and are also abundantly present in organs with erythropoietic activity such as 1550 
bone marrow and spleen [612, 613]. Furthermore, Hz-fed monocytes and the Hz-derived product 4-HNE 1551 
can inhibit erythroid progenitor growth in vitro by interfering with the cell cycle and with the expression 1552 
of crucial receptors, e.g. EpoR, the transferrin receptor CD71, stem cell factor receptor, and IL-3R [614-1553 
616]. The inhibitory effects on erythropoiesis mediated by parasite products like Hz are different from 1554 
and additional to changes induced by host inflammatory molecules e.g. TNF [617]. Since Hz also induces 1555 
the expression of inflammatory molecules, these inflammation-independent effects augment the 1556 
importance of malaria pigment in impairing erythropoiesis. Also P. vivax-iRBCs are able to inhibit 1557 
erythroid development in vitro, an effect most probably mediated by the released parasite components 1558 
from the rupturing schizont as no TNF nor IFN- were detected in the culture medium [618]. The 1559 
importance of parasite components in the induction of anemia due to P. vivax is further evidenced by the 1560 
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fact that only parasitemia was an independent predictor of Hb levels, and not the level of inflammation 1561 
[619]. 1562 
Hepcidin, the iron regulatory hormone, is upregulated during asymptomatic and uncomplicated malaria 1563 
and was suggested to contribute to malaria-associated anemia by limiting iron availability for 1564 
incorporation into erythroid precursors [620]. However, no association was found between hepcidin and 1565 
Hb levels and low hepcidin levels are found in SMA patients [621-624]. Anti-Epo auto-Abs are 1566 
negatively correlated with Hb levels in semi-immune mice, which could point to an additional mechanism 1567 
why erythroid progenitors are not responding accurately [625]. Also phagocytosis of erythroid precursors 1568 
and dyserythropoiesis, i.e. morphologic abnormalities of the nuclei and cytoplasm, are observed in the 1569 
bone marrow of malaria patients and contribute to the inadequate erythropoietic response [600].  1570 
Together, these data indicate that the interplay between the immune system and parasite-derived virulence 1571 
factors such as Hz play major roles in the pathogenesis of severe malarial anemia.  1572 
5. Immunoregulatory mechanisms dampen antimalarial immunity and immunopathology 1573 
As outlined above, an exaggerated proinflammatory response may result in tissue damage. Therefore, 1574 
different mechanisms are activated in the host to downregulate the proinflammatory response. However, 1575 
when this anti-inflammatory response is induced too early or when it is too strong, the immune system is 1576 
not able to control parasite replication. Also the parasite itself can interfere with specific immune 1577 
mechanisms, and a disorganized architecture of secondary lymphoid organs impairs humoral immunity. 1578 
Insufficient control of parasite replication may also lead to pathology. In this section, the mechanisms that 1579 
dampen the immune response, including activation of regulatory T cells, signaling through inhibitory 1580 
receptors, production of anti-inflammatory cytokines, interference by parasite products and impaired 1581 
humoral responses are discussed.  1582 
5.1. Regulatory T cells 1583 
In addition to the activation of Th cells and effector T cells, also T cells with an immunosuppressive 1584 
phenotype are induced during infection. Regulatory T cells (Tregs) contribute to immune homeostasis by 1585 
dampening excessive inflammatory responses. How they are induced is not yet completely clarified. 1586 
Intact P. falciparum-iRBCs or soluble extracts can induce the differentiation of immunosuppressive 1587 
CD4+CD25hi forkhead box P3 transcription factor (Foxp3)hi Tregs in vitro [626, 627]. Furthermore, their 1588 
induction is enhanced by and depends on the synergistic effect of bioactive TGF- and IL-10 produced by 1589 
monocytes, is independent of PfEMP-1 surface expression, and IL-2 is required for their proliferation and 1590 
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activation [626, 628]. One study indicates that TLR9 on DCs is essential for the activation of Tregs in 1591 
murine malaria with P. yoelii 17XL [57]. 1592 
Tregs are observed during malaria infection in both mice and men [183, 184, 629-634]. In both children 1593 
and adults with uncomplicated and severe malaria infections, a positive correlation was found between 1594 
peripheral parasitemia levels and the frequency of FoxP3+ Tregs within the CD4+ T cell pool [184, 635]. 1595 
Umbilical cord blood from neonates whose mothers suffered from P. falciparum placental malaria at 1596 
delivery contains an expanded population of parasite-specific CD4+CD25hi and CD4+CD25+ cytotoxic T 1597 
lymphocyte antigen 4 (CTLA-4)+ Treg cells [636]. These cells produce high levels of IL-10 in vitro that 1598 
suppress both effector T cell responses and MHC class I and II expression by monocytes. Also in P. 1599 
vivax-infected individuals, parasitemia correlates with the numbers of CD4+CD25+FoxP3+ T cells 1600 
coexpressing glucocorticoid-induced TNFR (GITR), CTLA-4, IL-10, TGF-, IFN- or IL-17, and these 1601 
cells inhibit proliferation of PBMCs in vitro [184, 634].  1602 
In mice infected with the lethal P. yoelii 17XL strain, Treg cell depletion with anti-CD25 augments DC 1603 
activation, promotes clearance of the parasite and results in survival [637-639]. Inducible genetic 1604 
depletion of FoxP3+ Treg cells also results in enhanced parasitemia control, and this is independent from 1605 
T cell-derived IL-10 [640]. Similarly, inhibition of the expansion of Tregs with anti-IL-2 during P. 1606 
chabaudi AS infection enhances antiparasite immunity during the chronic phase of infection [641]. With 1607 
the same parasite strain, transfer of Tregs or induction of Tregs with IL-2/anti-IL-2 complex reduces 1608 
parasite clearance and enhances IL-10 production [642]. The role of Tregs in P. berghei-infections is less 1609 
clear. In some studies, anti-CD25 treatment decreases parasite burden and protects from experimental CM 1610 
[643, 644], whereas other studies show limited or no effects of Tregs in CM [631, 633]. These differences 1611 
might be due to the use of anti-CD25 to deplete Tregs, since CD25 is also transiently expressed on 1612 
activated CD4+ T cells. Therefore, inducible genetic depletion of FoxP3+ Tregs in DEREG mice may be 1613 
more reliable as a technique and this did not affect the occurrence of P. berghei ANKA-induced CM 1614 
[645]. Tregs induced with IL-2/anti-IL-2 complex are found to be protective against CM, a mechanism 1615 
mediated by CTLA-4 [646]. Overall, a major role of Tregs in the pathogenesis of experimental CM has 1616 
not been found, although technological limitations and also the plasticity and heterogeneity of Treg 1617 
subsets may be confounding factors. Tregs may have a disease-promoting role in mice and men by 1618 
suppressing effective antiparasite immune responses and promoting high parasite loads.  1619 
Two mechanisms have been described by which Tregs diminish proinflammatory responses [647]. Direct 1620 
cell-cell contact, e.g. through CTLA-4 or membrane-bound bioactive TGF- on Tregs, seems to be 1621 
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essential to attenuate proinflammatory responses in CD4+CD25- T cells cocultured with APCs [648]. 1622 
However, whether this is mediated by direct cell-cell contact between CD4+CD25+ T cells and 1623 
CD4+CD25- T cells or indirectly through interaction with APCs has not yet been elucidated. Furthermore, 1624 
Tregs obtained from infected mice and patients secrete high levels of the immunomodulatory cytokines 1625 
TGF- and IL-10, which can interact with their corresponding receptors on different cell types [626, 627, 1626 
648]. Interestingly, FoxP3+ Tregs are not the major IL-10 producing cells. Highest IL-10 production is by 1627 
IFN-+FoxP3- CD4 T cells, as detected in both patients and mouse models [635, 649-651]. In mice, this 1628 
unusual IL-10 production by Th1 cells is dependent on IL-27 [651]. The latter cytokine plays an anti-1629 
inflammatory role in murine malaria, not only by inducing IL-10 in IFN-+FoxP3- Th1 cells but also by 1630 
suppressing the IL-12-driven terminal differentiation of Th1 cells [652]. As such, IL-27 plays a dual role 1631 
as it suppresses efficient parasitemia control in primary and secondary infections, while it also protects 1632 
against severe inflammatory liver pathology [653, 654], illustrating the importance of this cytokine in 1633 
steering the immunological balance of malaria toward equilibrium or imbalances. Besides T cells, 1634 
regulatory B cells also produce IL-10 in murine malaria and may contribute to the suppression of CM 1635 
[655]. With P. vivax also CD14hiCD16/FcRIIIA+ ‘inflammatory’ monocytes seem to be a source of IL-1636 
10 production, which is produced in combination with TNF [45]. 1637 
5.2. Inhibitory receptors 1638 
The proinflammatory response can also be downregulated by signaling through inhibitory receptors 1639 
expressed by various cells of the immune system. Activated T cells can express inhibitory receptors such 1640 
as CTLA-4, PD-1 and lymphocyte-activation gene-3 (LAG-3), and signaling through these receptors 1641 
impairs proinflammatory cytokine production and protective T cell activity [136, 656, 657]. Such CD4+ T 1642 
cells coexpressing PD-1 and LAG-3 have been found in higher frequencies in children living in regions 1643 
with persistent P. falciparum exposure and were found in combination with high frequencies of atypical 1644 
MBCs (see section 5.5) [658]. Signalling through these receptors may interfere with the generation of a 1645 
robust antiparasite response because therapeutic blockade of both PD-1/PD ligand 1 (PD-L1) and LAG-1646 
3/MHC class II ligation rapidly improves antiparasitic immunity in several mouse-parasite combinations. 1647 
Furthermore, perfectly balanced co-inhibitory and co-activation signals are important to prevent excessive 1648 
proinflammatory cytokine secretion. For example, PD-1 inhibitory signals are important to limit 1649 
excessive IFN- production resulting from OX40 (CD134)-mediated costimulation, since such excessive 1650 
IFN- would otherwise inhibit GC generation important for the production of high affinity parasite-1651 
specific MBCs and long-lived PCs as described in section 2.2.3 [194]. When induced at the right time, 1652 
signaling through the inhibitory receptors CTLA-4 and PD-1 expressed by activated T cells also protects 1653 
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against immunopathology in mice by dampening excessive proinflammatory cytokine production [656, 1654 
659, 660]. Another inhibitory receptor, BTLA is expressed on many leukocytes, binds to herpes virus 1655 
entry mediator (HVEM) and decreases antimalarial immunity in P. yoelii infections through both innate 1656 
and adaptive immune pathways [661]. In children, highest proportions of CTLA-4 expressing CD4+ T 1657 
cells are detected in peripheral blood during severe malaria [662], indicating that inappropriate T cell 1658 
inhibition may prevent the generation of sufficient antiparasite immunity. Furthermore, interaction 1659 
between IgGs and the inhibitory FcRIIB on macrophages and activated B cells impairs antiparasite 1660 
immunity in mice and men [663], and gene polymorphisms abrogating FcRIIB function are more 1661 
prevalent in populations living in malaria-endemic areas and are associated with protection against severe 1662 
disease [664]. 1663 
5.3. Anti-inflammatory cytokines and enzymes 1664 
Inflammation-extinguishing cytokines such as TGF- are produced by different cell types including 1665 
Tregs, monocytes/macrophages and platelets, and high plasma levels have been detected early during 1666 
infection in both nonimmune individuals and in mice infected with lethal malaria parasite strains [629, 1667 
665, 666]. TGF- production is necessary to protect the host against severe pathology by diminishing 1668 
inflammation [667], as severe P. vivax patients have lower TGF- concentrations compared to patients 1669 
with mild disease [215]. Decreased TGF- levels can originate from heme-dependent inhibition of TGF- 1670 
secretion by monocytes or by thrombocytopenia, which are both present in malaria. When TGF- is 1671 
produced early after infection, it facilitates blood-stage parasite growth by inhibiting protective immune 1672 
responses. This effect is strongly pronounced in IL-12-deficient mice, in which TGF- impairs 1673 
phagocytic responses, and the latter cannot be restored after supplementation with exogenous IFN- 1674 
[668]. TGF- is constitutively expressed by a wide range of cell types and stored as an inactive, latent 1675 
protein. Because its activity is not merely regulated at the transcriptional level but also by proteolytic 1676 
activation, high plasma levels can be obtained rapidly. Mature malaria parasites, both P. falciparum and 1677 
murine malaria parasites, appear to possess a thrombospondin-like molecule and metalloproteinase 1678 
activity which together can activate latent TGF- and are thus capable of directly inducing bioactive 1679 
TGF- [627, 669]. In this way, the parasite is able to diminish host-derived immune responses thereby 1680 
supporting parasite survival and transmission. Besides a role in Treg cell activation and function, TGF- 1681 
may also directly inhibit proliferation and IFN- secretion by NK cells [670]. Whether this occurs in 1682 
Plasmodium infections as observed in other parasitic infections, needs to be investigated. Neutralization 1683 
of early TGF-, together with inhibition of the compensatory rise in IL-10, restores early IFN- responses 1684 
and protects mice from a lethal P. yoelii infection [665].  1685 
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IL-10 is also induced during malaria and is observed after the early wave of proinflammatory cytokine 1686 
secretion [665]. IL-10 alone does not seem to be of major importance for antiparasite immunity in mice, 1687 
as depletion of IL-10 or supplementation with recombinant IL-10 does not significantly alter peripheral 1688 
parasitemia, although it diminishes IL-12 secretion by DCs and subsequent IFN- responses [104, 665, 1689 
671-674]. In patients with uncomplicated P. falciparum or P. vivax malaria, IL-10 has been implicated in 1690 
DC apoptosis, as plasma IL-10 levels correlate with circulating apoptotic DCs, and the total numbers of 1691 
circulating DCs are decreased [185]. Furthermore, IL-10 correlates with total parasite biomass in severe 1692 
vivax patients [274]. In mice, adequate IL-10 production is indispensable to prevent immunopathology, as 1693 
mice deficient in IL-10 develop CM when infected with P. chabaudi, a parasite that is otherwise nonlethal 1694 
in C57BL/6 mice. Treatment with anti-TNF or anti-IFN- Abs rescued these mice from CM, indicating 1695 
that the protective effects of IL-10 are due to the downregulation of the proinflammatory response [671, 1696 
672].  1697 
In macrophages, IL-10 inhibits proinflammatory gene transcription e.g. TNF, IL-1 and IL-6 by inducing 1698 
HO-1 which, by releasing CO, inhibits the translocation of NF-kB to the nucleus (see section 4.2.3) [675, 1699 
676]. HO-1 and exogenous CO potently protect mice against severe pathology in different organs 1700 
including brain, lungs and liver, in particular by reducing activation of pathogenic CD8+ T cells (see also 1701 
section 4.2.3) [213, 425, 677]. Interestingly, sickle cell Hb in transgenic mice induces HO-1 via the 1702 
oxidative stress sensor Nrf-2 and protects against CM, suggesting that this might be a mechanism how 1703 
sickle cell anemia protects against severe pathology in malaria [678]. The same pathway, Nrf-2-mediated 1704 
induction of HO-1, has been implicated as the protective mechanism of NO (see above, [423]). Both IL-1705 
10 and HO-1 protein expression are absent in brains of mice with CM [213, 679]. Why HO-1 is not 1706 
upregulated in murine CM brains is not known, since free heme, the substrate of HO-1, is liberated from 1707 
rupturing schizonts (and uninfected RBCs) and should normally induce HO-1 expression. In patients who 1708 
died from CM, strong HO-1 staining is observed in brain, lungs and liver in intravascular monocytes and 1709 
tissue macrophages (Kupffer cells and alveolar macrophages) and in monocytes and microglia inside 1710 
Dürck’s granulomas [497, 680, 681]. Furthermore, highest IL-10 levels are found in brains of CM 1711 
patients [544] indicating that IL-10/HO-1 responses are induced but are not sufficient to protect against 1712 
CM.  1713 
Most peculiarly, both IL-10 and HO-1 are involved in the exacerbation of Salmonella typhimurium 1714 
infections (causes nontyphoid Salmonella, a common and often lethal complication of P. falciparum 1715 
infection in Sub-Saharan Africa) resulting in acute, fatal bacteremia in mice [682]. Granulocytes normally 1716 
kill these intracellular bacteria by production of ROS. However, since P. yoelii 17XNL parasites induce 1717 
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HO-1 expression in immature bone marrow granulocytes, the maturation of these cells and the generation 1718 
of an effective oxidative burst is impaired and intracellular bacterial replication is increased. This 1719 
neutrophil dysfunction and Salmonella exacerbation is also dependent on myeloid-cell derived IL-10 1720 
[683]. The neutrophil dysfunction also occurs in P. falciparum malaria and correlates with hemolysis and 1721 
HO-1 induction [682]. HO-1 is induced especially abundantly in neutrophils and is highest in patients 1722 
with severe malaria, and HO-1 mRNA correlated with IL-10 mRNA levels in whole blood [684]. In 1723 
contrast, neutrophils from P. vivax patients are activated and their phagocytic activity and superoxide 1724 
production is significantly enhanced, although they have a decreased chemotactic activity [685]. Whether 1725 
also P. vivax exacerbates Salmonella infections remains to be investigated, however, intracellular killing 1726 
mechanisms do not seem to be impaired with P. vivax. 1727 
All together, these data indicate that IL-10 and HO-1 are linked and may provide protection against 1728 
severe immunopathology, but may also cause impaired immunity, in particular against bacterial infections 1729 
occurring as comorbidities of malaria. 1730 
Type I IFNs have also been implicated in immunomodulation in murine CM, but paradoxical data exist 1731 
whether type I IFNs are protective or pathogenic [686-688]. Administration of recombinant type I IFN 1732 
protects against experimental CM by reducing the expression of inflammatory molecules, e.g. TNF, 1733 
ICAM-1, and MIG/CXCL9 [686, 687]. However, type I IFN signaling hampers DCs to stimulate IFN- 1734 
production by CD4+ T cells and to control parasite growth, indicating that type I IFN also decrease 1735 
antimalarial immunity, and part of these effects are mediated through interferon regulatory factor 7 (IRF-1736 
7) [688-690]. In humans, specific IFN-αR1 polymorphisms are associated with protection against CM 1737 
[691]. 1738 
5.4. Parasite products 1739 
Besides activation of negative feedback mechanisms to limit excessive inflammation and to protect 1740 
against pathology, the parasite and its products can also actively interfere with the generated immune 1741 
response in numerous ways. 1742 
For example, Hz may downregulate protective immune responses in multiple ways (besides inducing 1743 
inflammation and oxidation as discussed in sections 3.2.2, 4.2.4 and 4.2.5). Phagocytosis of Hz generates 1744 
high amounts of 4-HNE and HETEs that, through activation of and interaction with PPAR-, inhibit 1745 
important monocyte functions in vitro involved in phagocytosis and antigen presentation (e.g. by 1746 
downregulating MHC class II expression) and in differentiating monocytes into DCs [692]. 4-HNE also 1747 
reacts with the cytoskeleton and impairs chemotaxis of monocytes [693]. PPAR- antagonizes NF-kB 1748 
56 
 
signaling by interacting with the p65 subunit of NF-kB, and Hz-derived products such as HETEs can both 1749 
induce proinflammatory immune responses through activation of NF-kB and downregulate immunity and 1750 
inflammation by acting on PPAR- Therefore, the eventual immunological effect will depend on the 1751 
timing of PPAR- activation during infection and the amount of trans-inhibition occurring over time in 1752 
the microenvironment. Interestingly, PPAR- agonists enhance parasite clearance and decrease 1753 
inflammatory responses in patients with uncomplicated malaria [694] by upregulating CD36-mediated 1754 
phagocytosis of iRBCs [695]. However, under inflammatory conditions PPAR- is downregulated and 1755 
Nrf-2 activators appear more efficient in upregulating CD36-mediated phagocytosis of parasites [696]. 1756 
Furthermore, since PPAR- agonists decrease inflammation they might have beneficial effects in 1757 
complications due to exaggerated inflammation. In experimental CM, PPAR- agonists decrease EC 1758 
activation and BBB damage and improve survival [697].  1759 
Furthermore, in P. berghei-infected mice, Hz levels are negatively correlated with MHC class II 1760 
expression in lungs and livers. In contrast, P. chabaudi AS-infections produce much lower amounts of 1761 
Hz, which do not correlate with MHC class II expression but rather correlate with hepatic inflammation 1762 
and damage [229, 230]. Anti-Hz IgM Abs have also been detected in serum of patients with complicated 1763 
P. falciparum malaria and can inhibit TNF and IL-1 production by monocytes in vitro [698].   1764 
The parasite may also interfere with the generation of a proper humoral response. As will be discussed in 1765 
the following section, PfEMP-1 may trigger T cell-independent polyclonal B cell activation which may 1766 
interfere with more specific and efficient B cell-mediated immunity.  1767 
5.5. Impaired humoral immunity 1768 
The generation of Ab-mediated immunity has been discussed in sections 2.1.3 and 2.2.3 and is in part 1769 
circumvented by the parasite by antigen variation and diversity (see section 3.3.2). Interference in the 1770 
generation of the antibody response, and in particular in B cell memory, further impedes efficient 1771 
antimalarial antibody-mediated immunity. 1772 
For the induction of an adequate humoral response a properly organized architecture in the secondary 1773 
lymphoid organs is imperative. However, features of splenic architectural disorganization, e.g. reduced B 1774 
cell numbers in the marginal zone surrounding B cell follicles (possibly due to apoptosis of MBCs), 1775 
decreased numbers and/or disorganized GCs, extrafollicular foci of plasmablasts, disappearance of the 1776 
marginal zone or a fading delineation between GCs and red pulp, have been observed in mice, monkeys 1777 
and in patients with severe P. falciparum disease [699-702], while in patients with uncomplicated 1778 
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malaria, splenic white pulp hypercellularity and active GC formation are apparent [275, 276]. This 1779 
disorganization may cause alterations in the proportions of the different B cell populations that are 1780 
observed.  1781 
Furthermore, chronic malaria exposure may promote atypical MBC differentiation over classical MBCs 1782 
[703]. These atypical MBCs express inhibitory receptors and fail to respond to B cell receptor clustering 1783 
resulting in impaired B cell responses including proliferation, cytokine production and Ab secretion.  1784 
[106, 130]. Why and how this occurs is currently unknown, although CD4 T cell exhaustion might 1785 
contribute to promote atypical MBC generation (see also section 5.2) [658]. Furthermore, whether 1786 
atypical MBCs differentiate from classical MBCs or whether they originate from different precursors is 1787 
still controversial [703, 704]. An expanded atypical MBC pool is found in people who are chronically 1788 
exposed to or infected with malaria, and a higher frequency of atypical MBCs is found in patients who 1789 
reported at least one previous malaria episode compared to no previous exposure [658, 705-708]. These 1790 
atypical MBCs upregulate inhibitory receptors such as Fc receptor ligand 3 (FcRL3) and FcRL5, and 1791 
show diminished BCR signaling, proliferation, and cytokine production [703, 709]. Furthermore, they do 1792 
not actively secrete Abs (although contradictory data exist) and also do not differentiate into antibody-1793 
secreting cells after in vitro stimulation as do classical MBCs normally do [703, 704]. Whether atypical 1794 
MBCs are also present during experimental rodent infections is currently not known. Further studies may 1795 
indicate whether the expansion of these atypical MBCs is responsible for the inefficient and slow 1796 
acquisition of antimalarial B cell memory. 1797 
Another phenomenon interfering with the generation of efficient and specific antimalarial humoral 1798 
responses is T cell-independent polyclonal B cell activation, which may cause hypergammaglobulinemia. 1799 
This generates a large panel of highly diverse Abs that do not only recognize parasite antigens, but also 1800 
unrelated antigens, including self-antigens (reviewed in [191]). IgGs against brain antigens, including 1801 
non-erythroid alpha spectrin, have been described in Gabonese children with cerebral malaria [559]. 1802 
Some of these Abs may cross-react with parasitic antigens or neo-antigens on the iRBC surface and, in 1803 
this way, contribute to the protective antiparasite response. The cysteine-rich interdomain region 1α 1804 
(CIDR1α) of PfEMP-1 has been identified as a mediator of T cell-independent polyclonal activation of B 1805 
cells and in particular MBCs in vitro [710]. Direct interaction between CIDR1α and MBCs was shown to 1806 
increase MBC survival and to induce MBC activation and secretion of IgM, TNF and IL-6. Parasites or 1807 
parasite variants that lack the PfEMP-1 CIDR1α domain such as P. vivax or the PfEMP-1 variant 1808 
VAR2CSA do not induce polyclonal B cell activation [191]. 1809 
 1810 
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As a conclusion to section 5, attenuation of proinflammatory responses early during infection is beneficial 1811 
for the parasite by promoting parasite growth and transmission, whereas later during infection it protects 1812 
the host from inflammation-associated pathology. However, excessive attenuation may also be 1813 
devastating for both host and parasite by causing excessive parasite growth. 1814 
 1815 
6. Classification of malaria complications according to the immunological balance 1816 
Throughout this review we have outlined different mechanisms that influence the interplay between host 1817 
and parasite responses. Although various balances are involved in the pathogenesis of malaria 1818 
complications (Figure 1), it is the balance between the immune response of the host and the virulence of 1819 
the parasite which is the main determinant of the outcome of infection (Figure 2A). Based on the current 1820 
knowledge described in the previous paragraphs, we attempt to classify the different outcomes of both 1821 
human and rodent malaria according to the immunological balance, as is shown in (Figure 2B and 2C).  1822 
When a sufficient antimalarial immune response is mounted early during infection and is timely 1823 
downregulated to prevent excessive inflammation, disease is mild or absent. This is the case in patients 1824 
with an asymptomatic or uncomplicated infection, in whom parasite replication enables parasite 1825 
transmission, but without (severely) harming the host. It mostly occurs in semi-immune people in 1826 
endemic regions. Such balance is also obtained in particular mouse-parasite combinations such as P. 1827 
chabaudi AS infections in C57BL/6 mice, infections with the nonlethal strain of P. yoelii 17XNL or with 1828 
the attenuated parasite P. berghei XAT.  1829 
An inefficient antiparasitic response due to insufficient immune activation and/or excessive 1830 
downregulation favors parasite replication and results in hyperparasitemia. Peripheral parasitema levels 1831 
can be extremely high and are accompanied by anemia due to hemolysis of iRBCs. When reticulocytosis 1832 
is insufficient to alleviate anemia, suboptimal oxygen delivery may result in systemic hypoxia. 1833 
Furthermore, some inflammation is induced due to the massive release of parasite and red cell 1834 
components during schizont rupture. This pathology is also observed in certain mouse models of malaria, 1835 
i.e. in P. berghei infections of mice which are Th2 prone (e.g. BALB/c), or in lethal P. yoelii 17XL or P. 1836 
vinckei infections. Inefficient antiparasitic immunity in the host in combination with substantial immune 1837 
evasion by the parasite results in high organ-specific parasite loads as is observed in P. falciparum-1838 
patients with CM or with acidosis. This may severely impair blood flow and may even cut off the blood 1839 
supply to certain regions in the organ resulting in localized hypoxia and hyperlactatemia. In the brain, 1840 
compensatory vasodilation may increase intracranial pressure and consequently aggravate hypoxia. 1841 
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Conversely, when an exaggerated immune response is induced, inflammation causes severe pathology 1842 
even if parasitemia is not maximal. This is observed in SMA with P. falciparum or P. vivax in children or 1843 
mice, in whom low peripheral parasitemia levels are accompanied by increased destruction of uninfected 1844 
RBCs and compromised erythropoiesis. In lungs of both patients and mice with MA-ALI or MA-ARDS, 1845 
excessive pulmonary inflammation may damage the alveolar-capillary membrane, which reduces gas 1846 
exchange, and in severe cases alveolar flooding may occur with subsequent suffocation. Also in other 1847 
severe P. vivax complications, e.g. in PAM and CM, an exaggerated inflammatory response might 1848 
prevail. Relatively high parasite loads may be observed in immunologically important organs such as the 1849 
spleen and bone marrow, which may modulate immune reactions.  1850 
In the most severe conditions, both excessive parasite burden and excessive inflammation occur. Most 1851 
typically, in murine CM, excessive immunopathological reactions involving CD8+ T cells are damaging 1852 
the brain and are also required for the generation of an excessive parasite burden, as depletion of 1853 
pathogenic T cells results in lower parasite burden [487, 571]. Such pathogenic CD8+ T cells have not 1854 
been detected in patients with CM caused by P. falciparum. Still, immune cells and platelets sequester in 1855 
the brain microvasculature and a widespread endothelial activation is evident in these patients. P. 1856 
falciparum may use activation-induced receptors on ECs, e.g. ICAM-1, for cytoadherence and 1857 
sequestration, which suggests that the parasite (mis)uses endothelial activation for evasion and 1858 
proliferation [443]. It remains therefore a matter of debate whether inflammation or endothelial activation 1859 
effectively plays a crucial role in the pathogenesis of human CM, and clarifying whether the observed 1860 
brain swelling is due to vasogenic edema and inflammation is therefore of uttermost importance. Also 1861 
PAM induced by P. falciparum is to be classified in the category of excessive parasite burden and 1862 
excessive inflammation. Sequestration onto CSA results in high parasite loads in the placenta. As a 1863 
consequence, high numbers of inflammatory cells are recruited to the placenta, which produce large 1864 
amounts of inflammatory mediators resulting in tissue damage, without obtaining parasite clearance. 1865 
 1866 
CONCLUDING REMARKS 1867 
 1868 
A clear understanding of the balance between the immune system of the host and the virulence 1869 
mechanisms of the parasite in the different malaria complications is of high relevance for the 1870 
development of effective immunological interventions. A better understanding of the immunomodulatory 1871 
mechanisms inhibiting long-lasting antiparasite immunity may be of critical importance for the 1872 
development of more efficient vaccines or other interventions enhancing antimalarial immunity. In 1873 
conditions of insufficient immunity, antiparasitic drugs are clearly the most efficient therapeutic option, 1874 
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and anti-inflammatory therapy has little effect. In contrast, when exaggerated inflammation is at the basis 1875 
of a severe complication of malaria, antimalarial drugs remain important to remove the etiological agent, 1876 
but may be insufficient to reverse pathology. Anti-inflammatory therapy may then have beneficial effects. 1877 
The definition of the type of immunological imbalance in patients with malaria complications and the 1878 
development and testing of such an anti-inflammatory therapy which could be effective in these patients, 1879 
however, still remain difficult challenges.  1880 
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Figure legends 3866 
 3867 
Figure 1. Multiple balances determine the outcome of malaria infections. 3868 
An imbalance between host immunity and parasite evasion mechanisms during the erythrocytic phase of 3869 
malaria results in pathology and may rapidly evolve into life-threatening complications. Multiple 3870 
immunological, parasitological and physiological balances determine the outcome of an infection. The 3871 
parasite synthesizes several immunomodulatory molecules, including glycosylphosphatidylinositols 3872 
(GPIs), hemozoin (Hz) and immunostimulatory DNA. As a consequence, the host develops a prominent 3873 
immune response which limits parasite proliferation. This response is based on innate immune 3874 
mechanisms, e.g. phagocytic cells and natural killer (NK) cells, but in particular on antibody (Ab)-3875 
dependent phagocytosis and invasion-inhibiting Abs. These processes are orchestrated by a vast array of 3876 
inflammatory mediators and leukocytes and counterbalanced by anti-inflammatory cytokines and 3877 
regulatory T cells (Tregs). The counterbalance is crucial to avoid inflammation and immunopathology. 3878 
Furthermore, the parasite has evolved multiple mechanisms to evade immune clearance, including 3879 
sequestration, antigen variation and diversity, and may hijack the counterbalancing mechanisms of the 3880 
host to downregulate immunity. Hz may also inhibit dendritic cell (DC) function resulting in impaired T 3881 
and B cell responses. The erythrocyte is subject to a homeostatic balance between erythropoiesis and red 3882 
cell clearance. Malaria infections greatly enhance red blood cell (RBC) clearance, not only through 3883 
destruction and clearance of infected cells, but also through enhanced clearance of uninfected cells, 3884 
presumably by macrophages. When this is not sufficiently compensated by erythropoiesis, severe malarial 3885 
anemia may develop. Parasite sequestration may compromise the blood supply, induce hypoxia and lactic 3886 
acidosis and cause metabolic disturbances. These conditions may occur in different organs, including the 3887 
brain, the lungs and the placenta, and can be further aggravated by coagulation changes, e.g. as observed 3888 
in disseminated intravascular coagulation (DIC), local inflammation, e.g. by releasing reactive oxygen 3889 
species (ROS) and nitric oxide (NO), and immunopathological reactions that damage vascular integrity. 3890 
To optimize the oxygen supply, vasodilation is triggered to increase the blood flow through the organs. 3891 
These imbalances are central in a variety of complications, including cerebral malaria (CM), placenta-3892 
associated malaria (PAM), malaria-associated acute lung injury (MA-ALI)/acute respiratory distress 3893 
syndrome (ARDS) and acidosis. Although these different balances play crucial roles in the pathogenesis 3894 
of malaria complications, it is the balance between the immune response of the host and the virulence 3895 
mechanisms of the parasite that determines whether malaria evolves to severe pathology.  3896 
 3897 
 3898 
 3899 
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 3900 
 3901 
Figure 2. The immunological balance. 3902 
Panel A. When a parasite is not perfectly adapted to its host, different outcomes are possible and these 3903 
depend on the balance between parasite growth and immune control mechanisms. An insufficient immune 3904 
response in combination with immune evasion mechanisms may lead to excessive parasite growth and a 3905 
high parasite burden. This causes metabolic disturbances, severe pathology and even death. In contrast, 3906 
when an exaggerated immune response is induced, the balance is tilted resulting in immunopathology and 3907 
inflammation. This may also progress to severe pathology and death, albeit at a lower parasite burden. In 3908 
the most severe conditions, excessive immune evasion combines with an exaggerated inflammation, 3909 
resulting in both immunopathology and high parasite burden. Both inflammation and metabolic 3910 
disturbances may contribute to the final pathological symptoms. In panels B and C we propose a 3911 
classification of the malaria outcomes, in particular the complications, according to the immunological 3912 
balance in both patients (B) and mouse models (C). The details of the balance between the parasite and 3913 
the immune system is thoroughly discussed throughout the text and the classification is summarized in 3914 
section 6. Question marks symbolize some important uncertainties regarding the pathogenesis of specific 3915 
complications in patients. 3916 
 3917 
Figure 3. Antiparasite immunity. 3918 
Phagocytes like monocytes/macrophages and dendritic cells (DCs) carry specialized receptors, e.g. CD36, 3919 
which detect parasite proteins on the surface of merozoites and iRBCs. Upon phagocytosis, 3920 
transcriptional activation of inflammation-associated cytokines occurs together with the generation of an 3921 
oxidative burst to kill the parasites. Due to the secretion of interleukin-12 (IL-12), IL-15 and IL-18, also 3922 
other cells of the innate immune system e.g. natural killer (NK) cells,  T cells and NKT cells become 3923 
activated and start to secrete high amounts of cytokines including interferon- (IFN-) necessary to 3924 
activate and enhance phagocytic processes. Furthermore, specialized antigen-presenting cells (APCs) 3925 
digest and present parasite antigens in the context of major histocompatibility complex (MHC) class II (or 3926 
in the context of CD1d by NKT cells for non-protein antigens), which may activate adaptive T and B cell 3927 
responses. IFN- is produced by NK cells,  and  T cells and NKT cells. It further stimulates Th1 3928 
differentiation and the subsequent production of specific antibodies (Abs) by B cells to generate a strong 3929 
antiparasite response. Opsonizing Abs together with complement deposition accelerate parasite 3930 
recognition by phagocytes, whereas other Abs interfere with erythrocyte invasion and sequestration or 3931 
induce intraerythrocytic parasite degeneration. Ultimately, parasites are cleared from the blood unless 3932 
evasion mechanisms by the parasite, i.e. antigenic variation, alters the composition of the parasite surface 3933 
120 
 
proteins. Also IL-1, tumor necrosis factor (TNF) and IL-6 are produced mainly by phagocytic cells, 3934 
which cause fever in the human host and which, when not sufficiently balanced by anti-inflammatory 3935 
mechanisms, may cause collateral tissue damage. Parasite-specific CD8+ T cells are also activated during 3936 
infection by cross-presentation of parasitic antigens in the context of MHC class I and may cause 3937 
immunopathology. ADCI, Ab-dependent cellular inhibition; ADCC, Ab-dependent cellular cytotoxicity. 3938 
 3939 
Figure 4. Overview of virulence factors of a P. falciparum-infected RBC.  3940 
Besides intrinsic parasite growth rate and iRBC deformability, virulence is determined by a variety of 3941 
factors. RBC subset tropism is in part determined by molecules of the apical complex and codetermines 3942 
the parasite burden. Immunomodulating molecules released upon schizont rupture, such as heme, residual 3943 
bodies containing hemozoin (Hz), uric acid precipitates, glycosylphosphatidylinositol (GPI) molecules 3944 
and possibly also DNA and/or nucleosomes, are crucial factors in malaria-associated inflammation and/or 3945 
immunosuppression. Variant antigen superfamilies encode parasite adhesins such as P. falciparum 3946 
erythrocyte membrane protein-1 (PfEMP-1) and repetitive interspersed families of polypeptides (RIFINs), 3947 
which mediate cytoadhesion onto endothelial cells or other RBCs, resulting in immune evasion and blood 3948 
vessel obstruction. Microparticles and exosomes contribute to inflammation and intercellular 3949 
communication. These virulence factors are associated with the pathophysiology of malaria. Parasite 3950 
molecules, which interact directly with the host are indicated in red. 3951 
 3952 
 3953 
Figure 5. Imbalances result in severe pathology. 3954 
Severe complications may arise when the immune response of the host and evasion mechanisms by the 3955 
parasite are not perfectly balanced. This figure illustrates two types of imbalances. (A) Excessive parasite 3956 
replication may result from immune evasion and inefficient antiparasite responses. One of the major 3957 
immune evasion mechanisms is cytoadherence or sequestration. Adhesion of the iRBCs to endothelial 3958 
cells is mediated by binding of parasite adhesins, e.g. PfEMP-1 to specific endothelial receptors, e.g. 3959 
endothelial protein C receptor (EPCR), CD36, intercellular cell adhesion molecule-1 (ICAM-1) and 3960 
vascular cell adhesion molecule-1 (VCAM-1). Rosetting through the binding of non-infected RBCs to 3961 
infected RBCs is also mediated by parasite adhesins (e.g. RIFINs) and contributes to vessel obstruction. 3962 
This leads to high organ-specific parasite loads and may severely impair the blood flow or may even cut 3963 
off the blood supply to specific areas in the organ resulting in localized hypoxia and hyperlactatemia. 3964 
Furthermore, inflammation is induced due to the massive release of parasite and red cell components 3965 
during schizont rupture and by activated platelets. Together with the production of hypoxia-inducible 3966 
proteins, e.g. vascular endothelial growth factor (VEGF), this may alter vascular permeability. (B) An 3967 
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exaggerated inflammatory response, e.g. due to insufficient anti-inflammatory regulation, also causes also 3968 
severe pathology. Chemokines, including monocyte chemotactic protein-1 (MCP-1)/CCL2 and interferon 3969 
gamma inducible protein-10 (IP-10)/CXCL10 attract monocyte/macrophages, NK cells, CD4+ and CD8+ 3970 
T cells which adhere to the microvascular lining by interaction with specific adhesion molecules, e.g. P-3971 
selectin, ICAM-1 and VCAM-1. Leukocyte sequestration and excessive release of proinflammatory or 3972 
cytotoxic mediators such as tumor necrosis factor (TNF), interferon- (IFN- and perforin/granzyme, 3973 
result in blood flow perturbations and endothelial damage. Sequestration of iRBCs may further aggravate 3974 
this process, and accumulation of iRBCs may be enhanced by leukocyte-induced vascular obstruction and 3975 
endothelial expression of adhesion molecules. Adhering platelets provide additional receptors for 3976 
sequestration and secrete chemokines, e.g. platelet factor 4 (PF4/CXCL4), cytokines, e.g. transforming 3977 
growth factor- (TGF- and other factors, e.g. VEGF, and fuel both vascular obstruction by parasite 3978 
sequestration (panel A) and inflammation (panel B). Furthermore, high amounts of microparticles (MPs) 3979 
of different origins, e.g. from iRBCs and platelets, are produced and may transfer platelet and parasite 3980 
proteins to the endothelial cell surface, promoting the inflammatory and procoagulant state of the 3981 
endothelium. Excessive parasite replication (panel A) and exaggerated inflammation (panel B) may occur 3982 
separately or simultaneously and cause life-threatening complications (see also Figure 2). 3983 
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